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Abstract of thesis entitled: 
Mechanisms Responsible for the Alteration of Lipolysis in Diabetic (+db/+db) Mice 
Submitted by L A M Tsz Yan 
for the degree of Master of Philosophy 
at The Chinese University of Hong Kong in October 2007 
Type 2 diabetes mellitus (T2DM) is a multi-factorial disease in which obesity is one 
of the risk factors in its development. Both T 2 D M and obesity have been suggested 
to be related to the aberration of lipolysis of adipose tissue. This study aimed to 
investigate how diabetic/obese conditions affect the adipose tissues lipolysis. Female 
(〜6 months old) obese (+db/+db) mice (~60g) (C57BL/KsJ) were employed as a 
model of T 2 D M and obesity, and their lean littermates (+tn/+db) mice (~30g) were 
used as controls. Abdominal (omental) adipocytes were isolated and tested with 
different lipolytic agents. 
A range of P-adrenoceptor (P_AR) agonists (salbutamol, a p 2-AR agonist; B R L 
37344 and C G P 12177A, both are p 3-AR agonists; adrenaline and isoprenaline, both 
are non-selective P-AR agonists) and post-receptor agents (forskolin, an adenylyl 
cyclase activator and 8-bromo-cAMP, a cell permeable c A M P analogue) triggered 
concentration-dependent lipolytic responses in isolated adipocytes of both species, 
with a smaller magnitude observed in +db/+db mice. Suppression of B R L 
37344-induced lipolysis by nadolol (a (3i/p2-ARs antagonist) and bupranolol (a 
P1/P2/P3-ARS antagonist) and the suppression of isoprenaline-induced lipolysis by 
i 
ICI 118,551 (a P2-AR antagonist) and SR 59230A (a p 3-AR antagonist) confirmed 
the involvement of (3-ARs in these lipolytic responses. Results from reverse 
transcription polymerase chain reaction (RT-PCR) and Western immunoblotting 
techniques revealed that the p 2-AR ( m R N A but not protein) and p 3-AR ( m R N A and 
protein) expression level in +db/+db mice was lower than that observed in +m/+db 
mice. 
Lingzhi (water-extract, 4-week oral gavage) did not modify the forskolin-induced 
lipolysis in both strains of mouse. In contrast, folic acid (4-week oral gavage) 
enhanced the p-AR-mediated lipolysis in +db/+db mice, probably related to an 
alteration in the (3-AR/adenylyl cyclase/cAMP/PKA signaling pathway and the 
increase in P3-AR protein expression. 
Thiazolidinediones are insulin sensitizers for treating T 2 D M through the activation 
of peroxisome proliferator-activated receptor" (PPAR-y). However, application of 
ciglitazone, pioglitazone and troglitazone (PPAR-y agonists) did not induce lipolysis 
in both +m/+db and +db/+db mice. In addition, there was no difference in PPAR-y 
expression ( m R N A and protein) in the adipose tissues between the species. 
The possible beneficial effect of statins (3 -hydoxy-3 -methylglutaryl Coenzyme A 
(HMG-CoA) reductase inhibitors) on lipolysis was examined. However, the statins 
tested (simvastatin, simvastatin Na+ and pravastatin) did not elicit lipolysis in both 
species of mouse. N o difference was found in the H M G - C o A reductase expression 
( m R N A and protein) in the adipose tissues between the species. Furthermore, the 
biochemical existence ( m R N A and protein), with a differential expression profile, of 
ii 
extra-hepatic H M G - C o A reductase in various internal organs was demonstrated. 
However, the obese/diabetic conditions of the mice did not alter the protein 
expression of this enzyme in all organs studied. 
In conclusion, the abdominal adipose tissue lipolysis elicited by the (3-ARs agonists 
and post-adrenoceptor agents was reduced in +db/+db mice. A decreased expression 
of P2-AR and P3-AR in the adipocytes was responsible for the attenuation of this 
P-AR-mediated lipolysis. Folic acid (4-week oral, gavage) improved the 
P-AR-mediated lipolysis in +db/+db mice, probably through the alteration of the 















B R L 37344誘導的脂解作用能被納多洛爾〔nadolol，Pi/(32受體拮抗劑〕及布拉 
洛爾〔bupmndol ’ p,/p2/p3受體拮抗劑〕抑制，而由異丙基腎上腺素誘導的脂解 
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Chapter 1 Introduction 
1. General Introduction 
1.1. Obesity 
1.1.1. Overview 
The global epidemic of overweight and obesity - 'globesity' - is rapidly becoming a 
major public health problem in many parts of the world. In 2005, approximately 1.6 
billion adults (age 15+) were overweight; and at least 400 million adults were obese 
(World Health Organization (WHO), 2006). Body mass index (BMI) is commonly 
used to define obesity. B M I is a simple index of weight-for-height which is 
commonly used to classify underweight, overweight and obesity in adults. It is 
defined as the weight in kilograms divided by the square of the height in metres 
(kg/m
2




considered overweight, 30-35 kg/m is termed obese, and a B M I of 35 kg/m or 
higher is termed severely or morbidly obese. However, according to the Asian 
standards, individuals are deemed overweight with a B M I of 23.5 kg/m , obese with 
a B M I of 25 kg/m
2
, and severely obese with a B M I of 30 kg/m
2
 or higher (Janus, 
1997). 
1.1.2. Pathophysiology 
As obesity has been shown to be a serious health problem and a strong risk factor of 
other diseases, including type 2 diabetes mellitus (T2DM) and cardiovascular disease 
(Frayn, 2005), numerous studies have been employed to explore the causes of obesity. 
The common understanding of weight gain is a result of a sustained imbalance 
between energy intake and energy expenditure favouring positive energy balance. 
Various biological and behavioral factors involved in its pathogenesis are stated as 
1 
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below. 
Firstly, the obesity genes and leptin theory. Leptin, the product of the obesity genes, 
is a hormone produced by the adipose tissue that reduces appetite and increases 
energy expenditure (Caro et al., 1996). Its production is modulated under the 
feedback effect on hypothalamic energy regulation (Frayn, 2005). With a gene 
defective for either production or detection of leptin in an obese individual, the brain 
is unable to assess the body's adipose tissue status (Van Gaal et al., 2006). 
Secondly, the set-point theory. It is proposed that there is an internal mechanism 
located in the hypothalamus which maintains a preset body weight level, that is the 
set point, within a tight range (Mrosovsky et al., 1977). The body regulates the body 
weight by a feedback control mechanism which modulates food intake or energy 
expenditure to correct any deviations in body weight from the pre-determined 
set-point (Harris, 1990). In other words, obese individuals are often harder to lose 
weight owing to the higher pre-determined set point. 
Thirdly, the fat cell theory. Body fat increases in two ways. One way is the total 
increase in adipocyte number (hyperplasia). In fact, the degree of hyperplasia has 
been shown to be well correlated with the severity of the obese status (Hirsch et al., 
1976), especially in those with early onset of obesity. It is suggested that the number 
of fat cells developed during childhood largely determines the susceptibility to fat 
• gain in adult stage of an individual. Another way is the enlargement of existing fat 
cells (hypertrophy). In adults, the major change in adipose cellularity following 
weight loss is the shrinkage of adipocytes but not the decrease in adipocyte number, 
2 
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fat also matters (Bergman et al., 2007). 
Central obesity (or 'apple-shaped' or 'masculine' obesity) occurs when the main 
deposits of body fat are localized around the abdomen and the upper body. The best 
cut-off points for assessing abdominal visceral obesity in Chinese adults are 
suggested as follow: B M I of 26 kg/m
2
, waist circumference of 90 cm, and waist-hip 
ratio of 0.93; with waist circumference being the most sensitive and specific factor 
for the prediction of abdominal visceral obesity (Jia et «/., 2003). 
As mentioned above, obesity is a risk factor for insulin resistance, T 2 D M and a 
significant risk factor for cardiovascular diseases (Frayn, 2005). But for any given 
amount of total body fat, the subgroup of individuals with a selective excess of 
intra-abdominal, or visceral, adipose tissue is at substantially higher risk of being 
characterized by insulin resistance and by the features of metabolic syndrome 
(Despres, 2006). This is highlighted by abdominal obesity being the only mandatory 
diagnostic criterion on the definition of metabolic syndrome in the International 
Diabetes Federation (IDF) classification (Alberti et al., 2005). 
Therefore, the body's ability to cope with the surplus of energy might determine the 
individual's susceptibility to the development of metabolic syndrome. There is 
evidence suggesting that if extra energy is channeled into insulin-sensitive 
subcutaneous adipose tissue, the individual, even if in positive energy balance, will 
be protected against the development of the metabolic syndrome (Lemieux, 2004). 
However, in cases in which adipose tissue is absent, deficient or insulin resistant with 
a limited ability to store the excess energy, the triacylglycerol surplus will be 
4 
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deposited at undesirable sites such as the liver, the skeletal muscle, the heart and 
even in pancreatic p-cells，a phenomenon that has been described as ectopic fat 
deposition (Miranda et al, 2005). Thus, excessive intra-abdominal fat accumulation 
represents a marker of the relative inability of subcutaneous adipose tissue to act as 
an 'energy sink' when an individual has to handle an energy surplus due to excess 
energy intake and/or reduced energy expenditure. Consistent with this theory, severe 
insulin-resistant state was found in patients with lipodystrophic conditions in humans 
(Garg et al., 2004). Treatments with glitazones, a novel class of insulin sensitizer, 
increase subcutaneous fat deposition, which might help to explain the beneficial 
effects of this class of drug on muscle and liver insulin sensitivity (Miyazaki et al., 
2002). 
Excess visceral fat accumulation is associated with various atherogenic and 
diabetogenic abnormalities (Despres, 2006; Lebovitz et al., 2005). There is ample 
evidence in suggesting that an impaired non-esterified fatty acid metabolism could 
contribute to the insulin-resistant state among individuals with visceral obesity. 
Hypertrophied intra-abdominal adipocytes are characterized by a hyperlipolytic state 
that is resistant to the anti-lipolytic effects of insulin (Mittelman et al., 2002). The 
resulting non-esterified fatty acid flux to the liver may impair liver metabolism, 
leading to increased hepatic glucose production (Blaak, 2003). In a canine model 
study, high-fat diet induced visceral obesity can lead to hepatic insulin resistance 
with respect to glucose production and a marked increase in the 24-hour 
non-esterified fatty acid profile. It was proposed that such an increase in 
non-esterified fatty acids could be a stimulus for insulin secretion and could have an 
important role in the etiology of insulin resistance, particularly as it relates to hepatic 
5 
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carbohydrate and lipid metabolism (Bergman et al., 2006). Besides, increased levels 
of non-esterified fatty acids affect endothelial nitric oxide production, thereby 
impairing endothelium-dependent vasodilation (Van Gaal et al, 2006). 
Not only with quantitative changes in serum lipids, visceral fat accumulation is also 
associated with qualitative changes in lipoproteins, such as low-density lipoprotein 
(LDL)-cholesterol, and conveys greater insulin resistance than subcutaneous fat (Van 
Gaal et ^ /.,2006). 
Adipose tissue, apart from its role in lipid storage and mobilization, is also a 
remarkable endocrine organ releasing numerous cytokines, which might be 
originated from macrophages. These include pro-inflammatory molecules such as 
interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a) (Despres et al., 2006). In 
obesity, there is evidence of macrophage infiltration into the adipose tissues 
(Weisberg et al, 2003), which could contribute to the inflammatory profile that has 
been reported in abdominally obese patients. In addition, macrophages are found 
more frequently in visceral compared with subcutaneous adipose tissues (Bornstein 
et a/., 2000). 
Adiponectin, which is abundant in the blood, is specifically derived from adipose 
tissue (Frayn, 2005). It has been found to have many effects in vitro that are 
compatible with improved insulin signaling and potential protection against 
atherosclerosis (Matsuzawa, 2006). As opposed to pro-inflammatory adipokines, 
adiponectin levels are reduced in obese individuals, particularly among patients with 
excess visceral adiposity (Cote et al., 2005). This decrease could therefore be one of 
、 6 
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Diabetes mellitus is characterized by abnormally elevated plasma glucose 
concentrations, caused by inadequate insulin secretion, abnormal target cell 
responsiveness, or both (Groop, 1999). The chronic hyperglycemia and associated 
metabolic abnormalities in turn cause many complications of the disease, including 
damage to blood vessels, retinopathy, nephropathy and neuropathy (Chorzempa， 
2006). 
Diabetes mellitus is classified into two types, namely, type 1 diabetes mellitus 
(T1DM), or insulin-dependent diabetes mellitus (IDDM); and type 2 diabetes 
mellitus (T2DM), or non-insulin dependent mellitus ( N I D D M ) ( W H O , 2006). 
T 1 D M is a condition of insulin deficiency due to P-cells destruction in the pancreas. 
It is most commonly an autoimmune disease, in which the body fails to recognize the 
P-cells as 'self' and destroys them with antibodies and white blood cells (Silverthorn, 
2001). It is a complex disorder whose onset in genetically susceptible individuals is 
sometimes preceded by a viral infection (Skyler, 2007). Many type 1 diabetics 
develop their disease in childhood, giving rise to the old name of juvenile-onset 
diabetes. About 10% of all diabetics have T 1 D M (Silverthorn, 2001). 
In most T 2 D M patients, insulin levels in the blood are normal or elevated (Kahn et 
7 
Chapter 1 Introduction 
fl/., 2006). Many type 2 diabetics eventually become insulin-deficient and require 
insulin injections (Silverthorn, 2001). This group comprises 90% of the diabetic 
population, while about 80% of type 2 diabetics are obese (Moneva et cd., 2002). 
1.2.2. Pathophysiology 
T 2 D M is evolved from normal glucose tolerance (NGT) upon insulin resistance 
(Garvey et al., 1985). At the early stage, the predominant abnormality is reduced 
insulin sensitivity, characterized by elevated levels of insulin in the blood (Stumvoll 
e t 以人，2001). As insulin resistance aggravates, impaired glucose tolerance (IGT) is 
experienced, resulting in T 2 D M (Reaven, 1988). As the disease progresses, impaired 
pancreatic p-cell function may be encountered, causing the reduction of insulin 
secretion (Kahn et al., 2006). The fasting plasma glucose level of normal subjects is 
<5.6 mmol/L, while IGT is defined as a 2-h postprandial plasma glucose level of 
7.8 - 11.1 mmol/L, and type 2 diabetics have a fasting plasma glucose level >7 
mmol/L (Moneva et al., 2002). 
Insulin resistance, in fact, is thought to be one of the major mechanisms underlying 
the development of T 2 D M (Reaven, 1988). It refers to a steady-state plasma glucose 
level that is higher than would be expected for the prevailing plasma insulin (Kahn et 
al., 2006). It dramatically impairs glucose uptake in peripheral tissue (skeletal 
muscle, adipose tissue and liver) and results in over-production of glucose by the 
liver (DeFronzo, 1988). These are attributable to the maintenance of hyperglycemia 
in type 2 diabetics. As observed early in the disease process, patients are 
hyperinsulinemic but not hyperglycemic. Over time, the compensatory mechanisms 
collapses, proceeding to overt T 2 D M (Groop, 1999). 
8 
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The continued decline in pancreatic (3-cell function also contributes to the 
progression to T 2 D M , that the P-cell is unable to release insulin rapidly in response 
to intravenous glucose (Kahn, 2001). In addition, it has been found in T 2 D M that 
delivery of non-glucose secretagogues can acutely increase insulin release but does 
not result in equivalent responses to those seen with similar stimulation in healthy 
subjects (Kahn, 2001). Alongside with the 50% decrease in the number of |3-cells in 
T 2 D M , the capacity of (3-cell secretory function is also reduced by 75% or more by 
the time the diagnostic level for diabetes occurs (Roder et al., 1998). 
1.3. Lipolysis 
Adipose tissue lipolysis is the catabolic process leading to the breakdown of 
triglycerides stored in fat cells, releasing one molecule of glycerol and three 
molecules of fatty acids from each triglyceride molecule (Langin, 2006). Adipocytes 
play a critical role in energy homeostasis - by hydrolysis (lipolysis) of their 
triglyceride reserves, fatty acids are released into the circulation to be taken up by 
other tissues, and are oxidized or used for re-esterification in adipocytes to produce 
triglycerides (Zimmermann et al., 2004). Fatty acids also serve as important 
oxidative fuels for other tissues during times of energy deprivation such as fasting 
and exercise (Arner, 2005). A dysregulation of lipolysis may lead to metabolic 
abnormalities. Reduced lipolytic activity may contribute to accumulation of 
triglyceride in adipose tissue and thus obesity (Frayn, 2005). O n the other hand, 
excessive lipolysis may contribute to lipodystrophy syndromes, which are 
characterized by a significant loss or redistribution of triglyceride in adipose tissue 
depots, which may lead to higher circulating fatty acid and ectopic storage of 
triglyceride (Jaworski et al, 2007). These abnormalities are associated with the 
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development of insulin resistance (Stumvoll et al., 2001). Thus, a fine regulation of 
lipolysis is crucial for the maintenance of body energy homeostasis as well as for the 
prevention of metabolic diseases. 
1.3.1. Proteins participating in triglyceride lipolysis 
1.3.1.1. Hormone-sensitive lipase (HSL) 
Lipolysis is under tight regulation by hormones, such as catecholamines and insulin, 
of which secretion is under nutritional regulation (Lafontan et al., 1997). For many 
years，HSL has been considered to be the regulatory enzyme, hydrolyzing fatty acid 
from sn-1 and sn-3 position of triglyceride to generate 2-monoacyglycerol, which 
subsequently requires monoacylglycerol lipase for the complete hydrolysis to yield a 
third free fatty acid and glycerol (Langin, 2006). Glycerol must be shuttled back to 
the liver for oxidation or gluconeogenesis, and it has no alternative fate in the 
adipocytes. In liver and muscle，fatty acids released are utilized for local oxidation 
(Renold, 1965). 
1.3.1.2. Adipose triglyceride lipase (ATGL) 
Regulation of H S L in fasting state was thought to be the key process controlling 
lipolysis (Jaworski et al., 2007). However, studies on HSL-null mice suggested the 
existence of lipases other than H S L in adipose tissues. Fed on a high fat diet, these 
mice exhibited normal body weight, decreased fat mass but their white adipose tissue 
still retained approximately 4 0 % of triglyceride lipase activity compared to wild type 
mice (Harada et al., 2003; Osuga et al., 2000). Recently, a novel lipase termed 
adipose triglyceride lipase (ATGL) has been identified (Jenkins et al，2004; Villena 
et al., 2004; Zimmermann et al., 2004). Although both H S L and A T G L possess 
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triglyceride hydrolysis activity, only H S L shows a significant diglyceride lipase 
activity (Haemmerle et al., 2002). It is noted that A T G L m R N A was down-regulated 
in db/db and ob/ob mice, suggesting that a down-regulation of A T G L may contribute 
to the development of obesity (triglyceride accumulation) due to the reduced 
lipolysis in adipose tissues (Villena et al., 2004). 
1.3.1.3. Perilipins 
Upon a lipolytic stimulation, protein kinase A (PKA) phosphorylates H S L which 
translocates from the cytosol to the lipidic vacuole surrounded by a phospholipid 
monolayer (Jaworski et al, 2007). A lipid droplet-associated protein, perilipin, is 
present inside this layer and may act as a barrier to prevent lipolysis in basal 
conditions, favouring lipid deposition (Carmen et al., 2006). When H S L translocates 
to the lipidic drop surface, perilipins are phosphorylated by P K A and hence lose their 
blocking capability (Londos et al., 1999). It is therefore perilipin knockout mice 
possessed a reduced adipose tissue mass and high basal lipolysis level 
(Martinez-Botas et al., 2000). 
1.3.2. Abnormal regulation of lipolysis in obesity 
Obesity is well recognized as a condition associated with increased basal lipolytic 
rate，indicated by increased systemic glycerol and free fatty acid concentrations as 
well as the systemic appearance rates (Del Prato et al., 1990). Nevertheless, there is a 
tricky point that the quantification of excess lipolysis in obesity would be different 
when it is expressed in terms of lean body mass, adipose tissue mass or total body 
weight. Expressed in lean body mass units, obese subjects have increased basal rates 
of lipolysis (Bjorntorp et al’, 1969). O n the contrary, reduced basal rates of lipolysis 
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are observed when it is measured in terms of total body fat (Bjorntorp et al., 1969). 
Appearance rate of free fatty acids in obese subjects, when compared to lean subjects, 
raises less in response to catecholamines (Reynisdottir et al., 1994). The higher 
resting, post-absorptive free fatty acids turnover may partly account for this. It could 
be due to a declined number of p2-adrenoceptors, changes in the functional balance 
between a 2- and P-adrenoceptors, or post-receptor alterations (Reynisdottir et al., 
1994). Moreover, defects in H S L translocation as well.as its lowered activity or 
perilipin function may also play a role in the catecholamine resistance of lipolysis in 
the obese subjects (Blaak, 2003). Indeed, it has been demonstrated that the 
expression of the key lipolytic enzyme, HSL, is down-regulated in adipocytes from 
obese subjects (Large et al., 1999). This decreased lipolytic effect of catecholamines 
in adipose tissue in obesity may be a cause of excess accumulation of body fat. 
Besides, the lipolytic activity of the fat cells has been shown to vary according to the 
anatomic location of fat depots (Kahn et al., 2006). Compared to lower-body obesity, 
upper-body obesity is associated with a higher fasting free fatty acid appearance rate 
but reduced responsiveness to adrenaline infusion (Blaak, 2003; Jensen et al, 1989). 
It appears that the augmented adipose tissue mass in obese subjects delivers more 
free fatty acids into the circulation, resulting in elevated free fatty acids 
concentrations when compared with lean subjects such that many undesired 
consequences result (Randle et al., 1963). However, it can be interpreted alternatively. 
In fact, the rate of free fatty acids release per unit mass of adipose tissue has been 
considerably down-regulated (Frayn, 2005). It is physiologically appropriate as the 
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body would not be swamped with excess free fatty acid. In other words, it represents 
an attempt of the adipose tissue to compensate for its increased size, that if such 
compensation did not take place the consequences would be far more severe (Frayn, 
2005). 
1.3.3. Disturbed lipolysis in insulin resistance 
Insulin profoundly inhibits lipolysis in adipocytes, primarily through the inhibition of 
H S L (Lonnroth et al, 1986). Therefore, in T 2 D M , in which insulin resistance exists, 
the anti-lipolytic effect of insulin is diminished in terms of lean body mass and 
fasting free fatty acids concentrations are increased (Large et al., 1998). 
Consequently, lipolysis and hepatic re-esterification of free fatty acids to triglyceride 
is ‘promoted (Mittelman et al., 2002). Since the uptake and oxidation of 
non-esterified free fatty acid were diminished in skeletal muscle of T 2 D M subjects 
during post-absorptive conditions and during p-adrenergic stimulations, such an 
elevated free fatty acid flux from the adipose tissues in turn has a deleterious effect 
on insulin regulation of carbohydrate metabolism (Stumvoll et al., 2001). At the 
same time, it causes hypertriglyceridemia in T 2 D M and aggravates cytosolic 
triglyceride accumulation in non-adipose tissues (Lewis et al., 2002). It has also been 
reported that resistance to insulin's glucoregulatory actions usually co-exists with the 




The current market is not devoid of drugs for the treatment of obesity. Orlistat, a 
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hydrogenated derivative of a bacterial lipase inhibitor that also blocks gastric and 
pancreatic lipases in humans, appears to be safe and effective (Chaput et al., 2007). 
Improvements in weight, cholesterol, blood pressure and glucose control during 
clinical trials are observed. In obese patients with comorbid conditions (Lindgarde, 
2000)，orlistat treatment gave a small but significant reductions in total and L D L 
cholesterol; ratio of L D L to high-density lipoprotein (HDL); systolic and diastolic 
blood pressure. In T 2 D M patients (Hollander et al., 1998), glycated hemoglobin, 
fasting plasma glucose and insulin levels are lowered. Owing to its mechanism of 
action, the main adverse effects of orlistat are oily spotting, fecal urgency and 
increased defecation; but due to mitigation of these side effects over time, the drug is 
generally well tolerated by most patients (Hofbauer et al., 2006). 
1.4.1.2. Sibutramine 
Sibutramine is a centrally acting reuptake inhibitor of monoamines (Chaput et al., 
2007) that has approval from the U S A Food and Drug Administration (FDA) and the 
European Committee for Proprietary Medicinal Products for use in long-term obesity 
treatment. It hampers the reuptake of noradrenaline, serotonin and dopamine and so 
promotes satiety as well as reduces food intake (Stock, 1997). Weight loss is resulted 
in-line with the increased thermogenesis and blunting of the reduction in metabolic 
rate (Stock, 1997). Unfortunately, sibutramine increases blood pressure and heart rate, 
making it not considered safe for people with hypertension or cardiovascular disease. 
Other side effects include dry mouth, insomnia, asthenia and constipation (Bray et al., 
1999). 
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1.4.1.3. Others 
At present, only the two drugs above are approved for the long-term treatment of 
obesity. However, a number of other noradrenergic drugs. are approved in some 
countries, but, limited for a short-term use only (Hofbauer et al, 2006). Also, some 
serotonergic, anti-epileptic and herbal drugs are currently used but they are not 
approved by the F D A to treat obesity. Examples include phentermine, diethylpropion 
and fenfluramine. Phentermine and diethylpropion are sympathomimetic amines, like 
amphetamine, but differ from amphetamine in having little or no effect on dopamine 
release or reuptake at the synapse (Bray, 2000). Fenfluramine has no effect on the 
reuptake or release of either noradrenaline or dopamine in the brain. Rather, it raises 
serotonin release and partially inhibits serotonin reuptake (Bray, 2000). 
1.4.2. Diabetes 
According to the pathophysiology of diabetes mellitus, the ideal primary treatments 
for T 2 D M should correct insulin resistance, p-cells dysfunction, and normalize 
hepatic glucose output, as well as prevent, delay or reverse the diabetic 
complications. 
1.4.2.1. Modulation of the p-cells functions 
One of the well known drugs targeting P-cell function is sulfonylurea, which binds to 
specific membrane receptors on p-cells and causes membrane depolarization by 
directly inhibiting KATP channels (Siconolfi-Baez et al., 1990). Intracellular buildup 
of calcium results, leading to the stimulus-secretion coupling and insulin secretion 
through exocytosis (Moneva et al., 2002). Other examples include repaglinide 
(Fuhlendorff et al., 1998), nateglinide (Keilson et al., 2000) and insulin (Garvey et 
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al., 1985). 
1.4.2.2. Control of glucose output 
Concerning the aspect of hepatic glucose output, metformin has myriad effects on 
carbohydrate, lipid, lipoprotein metabolism as well as anti-diabetic actions targeted at 
hepatic glucose production and peripheral insulin resistance (Stumvoll et al., 1995). 
1.4.2.3. Modulation of carbohydrate absorption 
a-glucosidase inhibitors, such as acarbose and miglitol rectify carbohydrate 
absorption (Moneva et al., 2002). These agents delay the digestion of complex 
carbohydrates and disaccharides to absorbable monosaccharides by reversibly 
inhibiting a-glucosidase within the intestinal brush border, thus attenuating the rise in 
post-prandial blood glucose level (Lebovitz, 1997). 
1.4.2.4. Thiazolidinediones (TZDs) 
A novel class of insulin sensitizers, TZDs, was originally developed in the early 
1980s as antioxidants (Yoshioka et al., 1989). TZDs enhance insulin sensitivity 
mainly at the level of muscle and adipose tissue, with some degree in the liver 
resulting in an increased insulin-dependent glucose disposal (Saltiel et al., 1996). In 
various animal models, TZDs lowered blood glucose in the absence of increased 
insulin -levels (Fujita et al., 1983; Fujiwara et al., 1991). TZDs were found to be 
beneficial in decreasing plasma triglyceride, very low density lipoprotein (VLDL), 
free fatty acids and glucose as well as removal of small dense L D L (Freed et al.-, 
2002). T Z D binding to a nuclear receptor, peroxisome proliferators-activated 
I'eceptor-y (PPAR-y), enhances the expression and transcription of multiple genes 
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encoding proteins, which modulate glucose and lipid metabolism (Spiegelman, 1998). 
The present clinically available PPAR-y ligands, rosiglitazone and pioglitazone, are 
widely used for the treatment o f T 2 D M (Lehmann et al., 1995). 
1.5. Animal models used in type 2 diabetes and obesity research 
The mutation diabetes, which occurred in an inbred mouse strain (C57BL/KsJ) at 
Jackson Laboratory (USA), is characterized by a metabolic disturbance resembling 
T 2 D M in human. The diabetic mutant exhibits a severe disease syndrome with onset 
at an early age and a shortened life-span. Diabetes (db) is inherited as a unit 
autosomal recessive with complete penetrance. Diabetes homozygotes {+db/+db) are 
fat, hyperglycemic and nonfertile (Hummel et al., 1966). 
One distinguishing feature of the diabetes homozygote is the deposition of fat in 
axillary and inguinal regions, first noticeable at 3 to 4 weeks of age. Body weight 
shows a rapid increase during the first few weeks (Hummel et al., 1966). They have 
higher lipogenesis rates and gain weight rapidly mainly due to the increased 
accumulation of more triacylglycerol as they mature. Their total triacylglycerol 
content could reach 50% of their body weight. At maturity, their lipogenesis rates 
decreases to normal (Yen et al., 1976). 
It has been reported that the blood sugar level of control mice did not exceed 200 
mg/100 ml of blood at any age. In contrast, +db/+db mice showed a level of 300 
mg/100 ml at 10 weeks of age. At such high blood sugar level, the diabetic mice 
display other symptoms, such as polyuria, polydipsia, polyphagia and glycosuria 
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(Hummel et al., 1966). 
C5 7BL/Ks]-+db/+db mice are also genetically altered models with phenotypes of 
obesity (Herberg et al., 1977). Disruption of the leptin receptor (Ob-R) gene in these 
mice leads to the failure to respond to leptin. Over-expression of leptin in the adipose 
tissue and a concomitantly high concentration of leptin in the blood of the mice are 
observed (Fruhbeck et al., 2001; Lee et al., 1996). It is widely accepted that leptin 
functions as a satiety factor through Ob-R, which is mainly expressed in the 
hypothalamus (Lee et al, 1996). Because of a deficiency of the leptin-mediated 
I . 
satiety signaling, abnormal dietary habits such as hyperphagia occur in homozygous 
+db/+db mice, resulting in complex phenotypes. Therefore, +db/+db mice are 
considered a good model for T 2 D M , because they exhibit both hepatic and peripheral 
insulin resistance. They are commonly used animal models for obesity and T 2 D M 
research (Hashimoto et al., 1996; Lam et al., 2006). A high level of conservation 
exists between mouse and human genomes (Mural et al., 2002) making these mice as 
appropriate animal models for human diseases. 
1.6. Aim of study 
Obesity and T 2 D M are both major costly health problems affecting many people 
worldwide. Patients suffering from these diseases have a greater risk of developing 
cardiovascular diseases such as hypertension, dyslipidemia and coronary heart 
disease. Owing to the high prevalence, numerous studies have been carried out on the 
pathophysiology and pharmacotherapy of the two disorders. In fact, both conditions 
are characterized by the disturbance in lipid metabolism, and in particular, lipolysis. 
Alteration in the lipolytic pathways in adipose tissue is responsible for the 
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development and maintenance of increased triacylglycerol storage and accumulation 
of lipid intermediates, thereby promoting obesity, T 2 D M as well as the complications 
resulted from the two disorders. Therefore, the main objective of the current research 
was to investigate the alteration of lipolysis in abdominal adipose tissue and its 
underlying mechanisms under obese/diabetic conditions using C57BL/KsJ-+^/+J6 
mice，which are well established rodent models of obesity and T 2 D M . In addition, it 
was attempted to search for drugs which can rectify the disturbed lipolytic responses. 
This project was divided into three sections. In the first section, the in vitro lipolytic 
effects mediated through p-adrenoceptors were assessed and compared between 
obese diabetic +db/+db mice and their lean control littermates +m/+db mice. 
Various p-adrenoceptor agonists and antagonists, as well as post-receptor agonists 
were used to identify the modification of the P-adrenoceptor-mediated lipolytic 
pathways. The m R N A and protein expression of (32- and (^-adrenoceptors in the • 
adipose tissue of both types of mouse were measured by reverse transcription 
polymerase chain reaction (RT-PCR) and Western Blotting respectively. O n the other 
hand, it is hypothesized that Lingzhi (water-extract) and folic acid may provide 
beneficial effects in treating T 2 D M via their anti-oxidant property. Hence, the two 
drugs were administered to both +m/+db and +db/+db mice and their effects on the 
lipolysis of abdominal adipose tissue were evaluated. 
In the second section, the acute effect of several PPAR-y agonists (insulin sensitizers 
which are widely used in the treatment of T 2 D M ) on in vitro lipolysis of abdominal 
adipose tissue in both types of mouse was determined. In addition, the m R N A and 
protein expression of PPAR-y in the abdominal adipose tissue of both types of mouse 
19 
Chapter 1 Introduction 
were measured by RT-PCR and Western Blotting respectively. 
In the third section, the acute effect of statins (3 -hydoxy-3 -methylglutaryl Coenzyme 
A (HMG-CoA) reductase inhibitors which are used in the treatment of dysfunction of 
cholesterol metabolism) on in vitro lipolysis of abdominal adipose tissue in both 
types of mouse was determined. In addition, the m R N A and protein expression of 
H M G - C o A reductase in different internal organs of both types of mouse were 
measured by RT-PCR and Western Blotting respectively. 
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2. P-Adrenoceptors (p-ARs) 
2.1. Introduction 
2.1.1. Hormonal control of lipolysis 
2.1.1.1. Catecholamines 
It is known that adipocytes express a combination of five different adrenoceptor 
isoforms: oci, a 2, pi, P2 and p 3 (Lafontan et al., 1993). Lipolysis is signaled by 
P-adrenergics, while an anti-lipolytic signal is transduced by the a2-adrenergics, and 
the a 1-adrenergics are involved in a separate pathway (Arner, 2005). Although 
lipolysis is the observed outcome of catecholamine stimulation, it is actually the 
steady-state result of the competition between two opposing pathways triggered by 
the same signal/receptor (Lafontan et al., 1997). 
The binding of catecholamines to the P-adrenoceptors (p-ARs) causes lipolysis by 
the activation of adenylyl cyclase via a stimulatory G-protein (Gs) (Schimmel et al., 
1980). Adenylyl cyclase then catalyzes the conversion of ATP to cAMP. c A M P binds 
to the regulatory subunit of protein kinase A (PKA), releasing the active catalytic 
subunit. Active P K A in turn phosphorylates the hormone-sensitive lipase (HSL) as 
well as the perilipins, which are a class of hydrophobic proteins (Langin, 2006). 
Phosphorylation of perilipin relieves the restraint and allows the translocation of the 
phosphorylated H S L to the triglyceride and begins to hydrolyze the stored lipid 
(Jaworski et al., 2007). It should be noted that the same signal would be bound to the 
a2-adrenoceptor and affect an inhibitory G-protein (Gj), which inhibits the activity of 
adenylyl cyclase (Stich et al, 1999). Disappearance of c A M P eventually causes 
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c A M P to dissociate from the regulatory subunit of PKA, which then inactivates the 
catalytic subunit by re-association (Carmen et al., 2006). In the absence of continued 
phosphorylation, dephosphorylation inactivates the H S L (Lafontan et al, 1993) 
(Figure 2.1). 
Insulin 
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Figure 2.1 Control of adipocyte lipolysis. Signal transduction pathways for 
catecholamines via adrenoceptor (AR) and insulin are described. AC, adenylyl 
cyclase; ATGL, adipocyte triglyceride lipase; DAG, diacylglyceride; GC, guanylyl 
cyclase; Goti,inhibitory GTP-binding protein; Gas, stimulatory GTP-binding protein; 
HSL, hormone-sensitive lipase; IRS, insulin receptor substrate; FA, fatty acid; M G L , 
monoglyceride lipase; PDE-3B, phosphodiesterase 3B; PI3-K, 
phosphatidylinositol-3-phosphate kinase; PKA, protein kinase A; PKG, protein 
kinase G; TAG, triacylglyceride. (Adopted from Jaworski et al., 2007) 
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2.1.1.2. Insulin 
Insulin, the most important physiological inhibitor of catecholamine-induced 
lipolysis, is capable of stimulating lipogenesis and inhibiting lipolysis simultaneously 
(Del Prato et al., 1990) (Figure 2.1). W h e n it binds to the insulin receptor, the 
tyrosine kinase of the receptor induces phosphorylation and activation of the 
cGMP-inhibited phosphodiesterase type 3B (Langin, 2006), resulting in an inhibition 
of the c A M P cascade through the cleavage of c A M P and direct dephosphorylation of 
PKA-activated substrates (Degerman et al., 1997). In addition, insulin reduces 
dramatically the number of cell surface P_ARs, which further desensitizes the 
adipocyte to lipolytic stimuli (Langin et al., 1995). 
2.1.2. Folic acid (folate) 
Folic acid (folate) is a water-soluble B vitamin with the name derived from the Latin 
folium, leaf. The term 'folic acid' usually describes a group of compounds derived 
from 5,6,7,8-tetrahydropteroyl-y-glutamate, commonly referred to as tetrahydrofolate. 
Good nutritional sources of folate are vegetables, fruits, grain, dairy products and 
meat (Stanger, 2002). The recommended daily intake of folate suggested by the U S A 
Food and Drug Administration (FDA) is 400 |ig/70 kg for adults (USA FDA, 2006). 
2.1.2.1. Physiological roles of folate 
Folates have recently gained considerable attention because of its presumed 
participation in the pathogenesis of birth defects, cardiovascular disease, cancer and 
neuropsychiatric disorders (Stanger, 2002). Folates are essential cofactors in various 
metabolic pathways, they facilitate the formation and transfer of'one-carbon units' in 
the process of D N A biosynthesis with implications for the regulation of gene 
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expression, transcription, chromatin structure, genomic repair and genomic stability 
(Robertson et al, 2000). Furthermore, they are involved in the transfer and 
utilization of one-carbon units and play a key role in the remethylation of 
homocysteine to methionine, thus providing essential methyl groups for numerous 
biological reactions (Medina et al., 2001). 
2.1.2.2. Folate deficiency and its consequences 
Surprisingly, folate deficiency is regarded as the most common vitamin deficiency in 
developed countries (Stanger, 2002). It is known that deficiency and impairment of 
folate metabolism is associated with hypomethylation, thereby decreasing the supply 
of methyl group donor in D N A synthesis (Robertson et al., 2000). This in turns 
impairs D N A stability and directly influences carcinogenesis (Mason et al., 1996). In 
fact, low folate intake is associated with carcinomas of the pancreas (Choi et al., 
2000) and breast (Zhang et al., 1999). Fortunately, folate supplementation has been 
shown to exert protective effects towards these events. For example, a 60% reduction 
in tumour development is associated with an increased intake of folate (Lashner et al., 
1989). The total risk, reduction for detection of carcinoma was calculated as 18% for 
each 10 ng/ml increase in red blood cell folate (Lashner, 1993). 
2.1.2.3. Hyperhomocysteinemia 
Apart from the D N A damage and the risk of tumour formation, folate deficiency is 
well documented to be related to elevated homocysteine levels, as accumulated from 
the impaired remethylation metabolism (Racek et al., 2005). Numerous retrospective 
and prospective studies have consistently found a . relationship between 
hyperhomocysteinemia and the risk of cardiovascular disease, especially in patients 
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with type 2 diabetes mellitus (T2DM) (Hoogeveen et al., 1998; Stanger et al., 2004). 
Such risk increase follows a linear relationship starting at a plasma homocysteine 
concentration of 10 (imol/l (Nygard et al., 1997). 
Promotion of the formation of reactive oxygen species (ROS) has been suggested as 
the mechanism of vascular damage in hyperhomocysteinemia (Hayden et al., 2004). 
Such increased oxidative stress to vascular cells is also resulted from the 
auto-oxidation of homocysteine, formation of homocysteine mixed disulphides and 
protein homocysteinylation (Blom, 2000). Hyperhomocysteinemia is thought to 
induce an oxidative inactivation of endothelial nitric oxide (Setola et al.，2004), in 
part by inhibiting or consuming the expression of cellular glutathione peroxidase 
(Weiss et al., 2002). Fortunately, folate supplementation has been demonstrated to 
provide corrective effects on these disorders. In mild to moderate 
hyperhomocysteinemia patients, dietary folate supplementation has been shown to 
improve the flow-mediated endothelium-dependent dilatation with a concomitant 
lowering of total plasma homocysteine levels (Woo et al., 1999). Racek et al. (2005) 
reported that folate treatment in patients with hyperhomocysteinemia increased the 
plasma antioxidant capacity and glutathione level, as a result of decreased production 
of free radicals due to a reduced level of homocysteine. Folate may therefore be 
regarded as an effective antioxidant in patients with hyperhomocysteinemia. 
2.1.2.4. Pleiotropic effects of folate 
As mentioned above, due to the numerous mechanisms suggested for 
homocysteine-mediated vascular damage, most of the interventional studies have 
focused primarily on the relationship between homocysteine levels and risk of 
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cardiovascular disease, in which folate was only considered as a means of reducing 
homocysteine. Not until recently that the beneficial effects of folate on vascular 
functions independent of homocysteine have been attributed to folate itself (Stanger, 
2002). 
Vascular endothelial dysfunction is recognized as the etiology of atherosclerosis 
(Stanger et al., 2004). Interestingly, oral folic acid supplementation (5 mg/day, 4 
weeks) restored the impaired endothelium-dependent vasodilation in subjects without 
elevated homocysteine concentrations (Verhaar et al., 1999). In subjects with no 
significant changes in homocysteine levels, folate administration was also associated 
with increased antioxidative capacity as determined by total antioxidant status (TAS) 
in human subjects, indicating an antioxidative potential for folate (Stanger et al., 
2002). Vasculoprotective effects of folate have been demonstrated by a prevention of 
lipid-induced decrease in flow-mediated dilatation in human subjects with normal 
homocysteine levels (Wilmink el al” 2000), suggesting that folic acid also possesses 
distinctive effects independent of homocysteine lowering. 
2.1.2.5. Role of folate in type 2 diabetes and obesity 
Hyperhomocysteinemia has been shown to be associated with complications in 
T 2 D M (Hoogeveen et al., 1998). As mentioned earlier, homocysteine promotes the 
formation of R O S (Hayden et al., 2004). In line with these facts, T 2 D M patients 
have a significantly higher plasma homocysteine and basal R O S level, in which the 
two markers are strictly correlated (Signorello et al., 2007). In fact, oxidative stress is 
known to be a potential pathogenic mechanism linking insulin resistance with 
endothelial dysfunction (Ceriello et al., 2004). Although the serum folate level is 
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normal in T 2 D M , short term oral folic acid supplementation (10 mg/day, 3 months) 
has been shown to cause a significant fall in heat shock protein 70 (Hsp 70) level, the 
protein which increases as a result of oxidative stress (Hunter-Lavin et al., 2004). 
Oral folic acid supplementation (10 mg/day, 3 months) in T 2 D M patients resulted in 
reduced plasma homocysteine levels and increased glutathione levels, reflecting an 
improvement in anti-oxidant status (Child et al., 2004). O n the other hand, a 
restoration of the e N O S reaction by folate supplementation has been demonstrated 
acutely by flow-mediated dilatation studies in T 2 D M largely independent of 
homocysteine lowering (van Etten et al., 2002). Hence, folate supplementation is 
beneficial to T 2 D M patients in various aspects. 
As overweight or obese individuals usually consume adequate total energy, low 
micronutrient levels may result from inadequate nutrient intake (diet and 
supplements) and/or alterations in nutrient absorption or metabolism (Kimmons et al., 
2006). As shown in a multivariate analysis, women who were overweight had a 12% 
lower, and obese postmenopausal women had a 2 2 % lower serum folate 
concentrations compared to normal weight women. Increased BMI, percent body fat, 
and absolute amounts of central and peripheral fat were all significantly associated 
with decreased serum folate (Mahabir et al., 2007). Consistent with these findings, 
increasing B M I was associated with low serum folate levels in men (Kimmons et al., 
2006). These observations in turn explain why obese patients are at a higher risk than 
normal-weight subjects for cancer and cardiovascular disease, since low folate levels 
may lead to inefficiencies in purine and pyrimidine synthesis as well as methionine 
regeneration (Stanger, 2002). 
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2.1.3. Lingzhi 
Lingzhi is the Chinese name given to the basidiocarps of Ganoderma lucidum (G. 
lucidim), a basidiomycete fungus. It is a famous medicinal fungus which has been 
used in China, Japan, Taiwan and other Asian regions for years. In Japan the names 
being used include Munnertake, Sachitake and Reishi, whereas in Korea it has the 
name Youngzhi (Paterson, 2006; Sliva, 2006). Regular consumption is believed to 
preserve human vitality and promote longevity. This popular medicinal mushroom is 
used in traditional Chinese medicine, that it might be beneficial for the prevention 
and treatment of a variety of ailments and chronic diseases such as hypertension, 
diabetes, arthritis, bronchitis, asthma, gastritis, nephritis, hepatitis and cardiovascular 
problems (Huie et al, 2004; Jong et al., 1992; Li et al., 2004). Recent scientific 
studies demonstrated that Lingzhi possess anti-cancer (Wang et al., 1997), anti-aging 
(Gan et al, 1998) and anti-microbial/viral activities (Eo et al., 2000; Yoon et al., 
1994), including anti-human immunodeficiency virus (HIV) activity (el-Mekkawy et 
al., 1998). 
Of the chemical constituents found in G. lucidum, polysaccharides and triterpenoids 
have been most thoroughly investigated (Eo et al., 2000; Jong et a/., 1992; Lin et al., 
2003). Other compounds isolated include immunomodulatory protein (LZ-8) (van 
der H e m et al., 1995), lectins (Ngai et al., 2004), nucleosides and nucleotides, etc 
(Shimizu et al., 1985). Various biological activities and pharmacological functions of 
G. lucidum reported in the literature are summarized in Table 2.1. 
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Biological activity Type of compound 
1 • Antitumour activities Polysaccharides and triterpenoids 
2. Hypoglycemic activity Polysaccharides 
3. Immunomodulation and stimulation of Polysaccharides 
cytokine production 
4. Immunomodulation Protein (LZ-8) 
5. Cytotoxicity to hepatoma cells Triterpenoids 
6. Hepato-protection Triterpenoids 
7. Inhibition of histamine release Triterpenoids 
8. Inhibition of cholesterol synthesis Triterpenoids 
9. Stimulation of platelet aggregation Triterpenoids 
10. Anti-HIV activity Triterpenoids 
11. Induction of apotosis Triterpenoids 
Table 2.1 Biological activities and pharmacological functions of compounds in G. 
lucidum. (Adopted from Shiao，2003) 
2.1.3.1. Triterpenoids 
Terpenoids are comprised of four groups: volatile mono- and sequiterpenes (essential 
oils); less volatile diterpenes; involatile triterpenoids and sterols; and the carotenoid 
pigments. Most investigations concern the less volatile triterpenoid (triterpene) and 
sterol forms (Paterson, 2006). Triterpenes/triterpenoids are in fact the bitter 
components of Lingzhi. Since the first isolation of two new bitter triterpenes, 
ganoderic acids A and B, from the dried epidermis of G. lucidum in 1982 by Kubota 
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et a/.(Kubota et al., 1982), more than 130 oxygenated triterpenes (mostly 
lanostane-type triterpenes) have subsequently been isolated from the fruiting bodies, 
spores, mycelia and culture media of Lingzhi (Kim et al, 1999). 
Triterpenes possess anti-cancer effect owing to the activity against growing tumours 
(Lin et al., 2003). They have direct cytotoxicity against tumour cells (Gonzalez et al., 
2002). Furthermore, it was observed that the methanol extract from the fruiting body 
of G. lucidum inhibited angiotensin-converting enzyme, which is involved in the 
control of hypertension (Morigiwa et al., 1986). Triterpenes isolated from G. lucidum 
induced platelet aggregation by stimulation of hydrolysis of phosphatidylinositol 
4,5-bisphophate (Su et al., 1999). It has also been shown that triterpenes exert 
anti-allergy effect by the inhibition of histamine release (Tasaka et al., 1988). 
2.1.3.2. Polysaccharides 
Polysaccharides are macromolecules which have been used as pharmaceuticals for 
years. Anti-tumour and immuno-modulating activities of G. lucidum have been 
investigated extensively recently (Paterson, 2006). The major bioactive Ganoderma 
polysaccharides species are p-1-3 and (3-1-6-D glucans. Although both are bioactive, 
the amount of water insoluble polysaccharides was found to be higher than that of 
water soluble polysaccharides (Mizuno et a!., 1984). Examples of water soluble 
polysaccharides are p-glucan and glucurono-p-glucan, whereas the water insoluble 
polysaccharides consist of hetero p-glucan, xylo-p-glucan, xylomanno-p-glucan and 
manno-P-glucan. It is known that polysaccharide branching affects activity such that 
most of the anti-tumour P-glucans contain a branched glucan core with (1—3)-p-， 
(1-^4)-(3- and/or (1—>6)-(3-linkages, with an average molecular weight of 1050 kDa 
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(Mizuno et al, 1984). 
Polysaccharides are believed to exert anti-tumour activities through an enhancement 
of host-mediated immunity rather than a direct cytotoxicity to the tumour cells. 
Water soluble polysaccharides of G. lucidum has been reported to inhibit the growth 
of Sacroma 180 solid-type tumour effectively (Miyazaki et al., 1981). Anti-tumour 
activity was also demonstrated from water insoluble polysaccharides of G. lucidum 
extracted with alkali (Wang et al., 1993). 
As reviewed in the literature, the pharmacological activities of Lingzhi are mainly 
related to the aiiti-oxidative property. Kim et al. (1999) found that water soluble 
polysaccharides extracted from the fruiting body of G. lucidum was effective in 
preventing D N A from strand breakage caused by hydroxyl radical and U V irradiation, 
indicating the anti-tumour and immuno-modulating activities of Lingzhi are strongly 
related to its anti-oxidative property. Ganoderma polysaccharide peptide reduced 
oxidation of L D L by scavenging reactive oxygen species (ROS) in mice (You et al., 
2003). Polysaccharide extracts from the mycelium of G. lucidum was found to 
exhibit anti-tumour effect against fibrosarcoma in male and female C 3 H mice and 
inhibit the metastasis of the lungs tumour. The extracts could stimulate blood 
mononuclear cells to increase cytokines, tumour necrosis factor (TNF), interferon 
and interleukin protein (Lee et al., 2003). 
Lingzhi has been shown to be beneficial to diabetes mellitus due to its hypoglycemic 
effect. Polysaccharides from the basidiocarps of G. lucidum stimulated insulin release 
by facilitating Ca inflow to the pancreatic P-cells in normal fasted mice (Zhang et 
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al., 2004). In addition, an 8-week treatment of polysaccharides from G. lucidum 
prevented/delayed the progression of diabetic renal complications in 
streptozotocin-induced diabetic mice (He et al., 2006). 
2.2. Materials and methods 
2.2.1. Materials 
2.2.1.1. Composition of physiological salt solution 
NaCl 118 m M 
KC1 4.7 m M 
M g S 0 4 1.2 m M 
K H 2 P 0 4 1.2 m M 
N a H C 0 3 25 m M 
Glucose 11 m M 
CaCl2 1.8 m M 
All the above chemicals were purchased from Merck (Darmstadt, Germany). 
2.2.1.2. Materials used in lipolysis experiment 
50 ml syringe Terumo 
Bovine serum albumin (fraction V) Sigma-Aldrich 
Clostridium histolyticum collagenase type II Sigma-Aldrich 
Folic acid Acros Organics 
Free Glycerol Determination Kit Sigma-Aldrich 
Ganoderma lucidum (G. lucidum) (Lingzhi) capsule PuraPharm 
Research Corp. Ltd. 
Nylon mesh (180 pm) Millipore 
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Sources and properties of the drugs used in the lipolysis experiments are listed in 
Table 2.1. 
D r u g Description Stock vehicle Source 
8-bromo-cAMP, Na+ Cell permeable Distilled water Tocris-Cookson 
c A M P analogue 
Adrenaline Non-selective (3-AR Distilled water Sigma-Aldrich 
hydrochloride agonist 
BRL37344, Na+ Selective p 3-AR Distilled water Tocris-Cookson 
agonist 
( 土 ) B u P r a n o l o l Pi/p2/p3-ARs Distilled water A giftfrom 
hydrochloride antagonist Schwarz 
Pharma 
(Germany) 
C G P 12177A Selective p 3-AR Distilled water Tocris-Cookson 
agonist 
Dibutyryl-cGMP, Na+ Cell permeable Distilled water Calbiochem 
c G M P analogue 
Forskolin Adenylyl cyclase D M S O Tocris-Cookson 
activator 
ICI 118,551 p 2-AR antagonist Distilled water Tocris-Cookson 
hydrochloride 
Isoprenaline Non-selective P-AR Distilled water Sigma-Aldrich 
hydrochloride agonist 
N a d o l G l
 P1/P2-ARS Distilled water Sigma-Aldrich 
antagonist 
Salbutamol Selective p r A R Distilled water Tocris-Cookson 
hemi sulphate agonist 
Sodium nitroprusside Exogenous nitric Distilled water Sigma-Aldrich 
(SNP), dihydrate oxide donor 
S R 59230A p 3-AR antagonist Distilled water Tocris-Cookson 
hydrochloride 
Yohimbine ot2-AR antagonist Distilled water Tocris-Cookson 
hydrochloride 
Table 2.1 Sources and properties of the drug used in lipolysis experiments. 
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2.2.1.3. Materials used in reverse transcription polymerase chain reaction 
(RT-PCR) 
Agarose Invitrogen 
Chloroform Fisher Scientific 
D E P C Amersham 
dNTP mix (1 O O m M ) Amersham 
Ethidium bromide Invitrogen 





Oligo (dT)25V Invitrogen 
P C R buffer Genesys Ltd. 
Primers Invitrogen 
PTC-225 Peltier Thermal Cycler M J Research 
R N a s e O U T ™ Invitrogen 
SuperScript™ reverse transcriptase Invitrogen 
T A Q polymerase Genesys Ltd. 
TRIZOL reagent Invitrogen 
2.2.1.4. Materials used in Western blotting 
0.5 M Trir-HCl (pH 6.8) Bio-Rad 
1.5 M Tris-HCl (pH 8.8) Bio-Rad 
B C A ™ protein assay kit Pierce 
4 0 % Bis-acrylamide mix Bio-Rad 
A m m o n i u m Persulphate Bio-Rad 
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Anti-P actin antibody Sigma-Aldrich 
Anti-p2-adrenoceptor antibody Santa Cruz 
Biotechnology 
Anti-p3-adrenoceptor antibody Santa Cruz 
Biotechnology 
Anti-goat H R P conjugated IgG Santa Cruz 
Biotechnology 
Anti-mouse H R P conjugated IgG DakoCytomation 
Anti-rabbit H R P conjugated IgG DakoCytomation 
B C A ™ protein assay kit pierce 
Glycine U S B 
Medical X-ray film Fujifilm 
Methanol Fisher Scientific 
Non-fat dry milk Bio-Rad 
Polyvinylidene difluoride membrane Bio-Rad 
Protease inhibitor Roche 
Immun-Star™ Chemiluminescent Kit Bio-Rad 
Sodium dodecyl sulphate (SDS) Bio-Rad 
Stripping buffer Pierce 
T E M E D Bio-Rad 
Tris (Tris[hydroxymethy 1]aminomethane) U S B 
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2.2.2. Methods 
2.2.2.1. Lipolysis experiment 
2.2.2.1.1. Animals 
Female C57BL/KsJ mice (6 month-old) (non-diabetic, control (+m/+db): ~30g; 
diabetic (+db/+db): ~60g) were housed under a 12:12-h light-dark cycle with 
relative humidity of 50-60%. They were given standard chow and water ad libitum 
before being killed by decapitation. All procedures were performed in accordance 
with the general guidelines of the Animal Experimentation Ethics Committee of The 
Chinese University of Hong Kong. 
2.2.2.1.2. Drug administration 
In the study of folic acid treatment, folic acid was dissolved in distilled water and the 
stock solution was stored at -20°C. The working solution was freshly prepared from 
the stock every week and kept at room temperature. Mice were divided randomly 
into three groups (control, folic acid (5.7 pg/kg/day, equivalent to 400 jig/day for a 
70 kg man) and folic acid (71 ^ ig/kg/day, equivalent to 5 mg/day for a 70 kg man)). 
In the study of Ganoderma lucidum (G. lucidum) (Lingzhi) treatment, water-extract 
of Lingzhi was prepared by dissolving the powder of the capsules followed by 
sonication (10 min), in distilled water. The stock solution was stored at -20°C and the 
working solution was freshly prepared from the stock every day. Mice were divided 
randomly into three groups (control, Lingzhi (0.03 g/kg) and Lingzhi (0.3 g/kg)). 
Drugs (or water which served as control) were administered orally, using a feeding 
needle, daily for 4 consecutive weeks before they were sacrificed for experiments. 
Change in body weight, if any, during the course of drug administration was 
monitored and recorded daily. 
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2.2.2.1.3. Isolation of adipocytes 
Adipocytes were prepared according to the method of Rodbell (Rodbell, 1964), with 
minor modifications. Abdominal (omental) fat pads were removed and washed in 
physiological salt solution (gassed with 16% 0 2/6%C0 2, balanced with N 2, p02 � 
100 mmHg). Fat tissues were then minced into small pieces and digested in 
physiological salt solution containing 0.5 m g collagenase/ml (supplemented with 3 % 
bovine serum albumin (BSA)). It was subjected to gentle shaking in a water bath at 
37°C for 60 min. After collagenase digestion procedure, the adipocytes were filtered 
through a nylon mesh (180 |im), and the fluid in the lower layer was aspirated. 
Adipocytes were washed three times with the collagenase-free physiological salt 
solution. The washing procedures discarded the rest of digestion subtracts with 
infranatant and sedimented stromal-vascular cells as well as the dead adipocytes. 
Suspension of adipocytes was stained with trypan blue (0.4 %) for cell counting and 
confirmation of cell viability. 
2.2.2.1.4. Lipolysis measurement 
The cell count was adjusted with a hematocytometer. The cells (1-2 x 10
5
 cells/ml) 
were suspended in physiological salt solution (10 ml) containing 3 % BSA. They 
were divided into aliquots and incubated in a final volume of 200 jil at 37°C in a 
shaking water bath for 150 min with graded concentrations of one of the following 
lipolytic agents: salbutamol (100 nM-100 ^iM, a selective p 2-AR agonist) (Louis et 
al., 2000), C G P 12177A (1 nM-1 ^iM, a p 3-AR agonist) (Galitzky et al., 1997), B R L 
37344 (0.1 nM-1 j^M, a selective p 3-AR agonist) (Germack et al., 1997), adrenaline 
(100 nM-100 j^M, a non-selective (3-AR agonist) (Germack et al., 1997), isoprenaline 
(0.1 nM-10 fj.M? a non-selective P-AR agonist) (Germack et al., 1997)，forskolin (10 
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nM-100 a specific adenylyl cyclase activator) (Germack et al., 2000), 
8-bromo-cAMP (1 nM-100 fiM, a cell permeable c A M P analogue) (Khan et al., 
2002), dibutyryl-cGMP (0.1 nM-100 ^iM, a cell permeable c G M P analogue) 
(Torrecillas et al., 2000) and sodium nitroprusside (SNP, 0.1 nM-100 nM, an 
exogenous nitric oxide (NO) donor) (Lam et al., 2006). In order to test the possible 
involvement of particular a/p-ARs, the cells were pre-incubated with one of the 
following receptor blockers for 30 min before the addition of lipolytic agents: 
nadolol (10 [lM, a Pi/PrARs antagonist) (Tavernier et al., 1996), bupranolol (10 pM, 
a pi/p2p3-ARs antagonist) (Canova et al, 2005), ICI 118,551 (0.1 and 1 JIM, a p 2-AR 
antagonist) (Louis et cd., 2000), SR 59230A (0.1 and 1 pM, a (33-AR antagonist) 
(Galitzky et al., 1997) and yohimbine (100 an a 2-AR antagonist) (Dicker et al, 
2005). The reaction was then stopped in an ice water bath. Aliquots (20 [i\) of 
cell-free medium were taken to determine the glycerol concentration, as an index of 
lipolysis, by a Free Glycerol Determination Kit. 
2.2.2.1.5. Data analysis 
The lipolytic activity was expressed on a per cell basis, as micromole of glycerol 
released per 10
6
 cells. Dose-response curves for glycerol release were analyzed by 
computer-assisted iteration using the GraphPad Prism (San Diego, CA, USA). Data 
are expressed as means 士 S.E.M. and analyzed by one-way or two-way A N O V A with 
post hoc Bonferroni's correction for multiple comparisons. Difference was 
considered to be statistically significant at 尸 <0.05. 
2.2.2.2. RT-PCR 
RT-PCR was performed as described previously (Lam et al., 2006) with minor 
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modifications. Details are as follow. 
2.2.2.2.1. Tissue preparation 
Abdominal (omental) adipose tissues were harvested from +m/+db and +db/+db 
mice immediately after being sacrificed. Tissues were rinsed in ice-cold physiological 
salt solution to remove blood before subjecting to molecular biology experiments. 
2.2.2.2.2. RNA extraction 
Tissue sample (0.3 g) was homogenized and lysed in 1 ml TRIZOL reagent using a 
homogenizer at 〜15,000 revolutions per min. The homogenate was incubated for 5 
min at room temperature and centrifuged at 12,000 x g for 10 min at 4°C. The 
supernatant was transferred to an Eppendorf tube, and 200 …of chloroform was 
added to the sample and shaken vigorously for 15 sec. After 5 min incubation at 
room temperature, the sample was centrifuged at 12,000 x g for 15 min at 4°C. The 
upper aqueous phase containing R N A was extracted with 0.5 ml ice-cooled 
isopropanol. Two solutions were mixed gently by inverting up and down. R N A was 
precipitated by 10 min incubation on ice. The sample was centrifuged at 12,000 x g 
for 10 min at 4°C. The supernatant was discarded, leaving the white R N A pellet. The 
pellet collected was washed with ethanol (75%) (300 ^ 1), and centrifuged at 9,000 x 
g for 10 min at 4°C. After removing the supernatant, the R N A pellet was dried in air 
and re-dissolved in 30 DEPC-treated water. Sample was stored at -70°C until use. 
The integrity of R N A was checked by electrophoresis in a 1% agarose gel containing 
ethidium bromide. The R N A concentration was measured spectrophotometrically at 
260 n m (A260). The RNA purity was assessed by measuring the ratio of A26o/A，8o-
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2.2.2.2.3. Reverse transcription (RT) 
t 
c D N A was synthesized from isolated total R N A using SuperScript™ III RT-PCR 
system. Briefly, 1 pg of total R N A was mixed with 1 jil dNTP mix (10 mM), 1 pi 
oligo(dT)25v and 10 [i\ distilled water. The mixture was heated to 65°C for 5 min and 
then allowed to stand on ice for at least 1 min. The second component of the reaction 
mixture containing 4 pi 5X First-Strand buffer, 1 )il 0.1 M DTT, 1 j^l R N a s e O U T ™ 
Recombinant Ribonuclease Inhibitor (40 units) and 1 \x\ SuperScript™ reverse 
transcriptase (200 units) was subsequently added and incubated at 50°C for 60 min. 
The reaction was terminated by incubation at 70。C for 15 min. The sample was 
stored at -20°C until use. 
2.2.2.2.4. Polymerase chain reaction (PCR) 
The reverse transcription product was used for the polymerase chain reaction (PCR) 
experiments. c D N A of each sample was mixed with IX P C R buffer, 1 m M MgCl 2, 
0.2 m M dNTP mix, 1 unit of T A Q polymerase and lOnM of respective paired 
primers. Primers used for P C R were designed based on the sequences available in 
GenBanlc database using GeneTool Lite (Quebec, Canada). The primer sequences 
used are listed below. The reaction mixtures in P C R tubes were then put into a 
thermal cycler, which was programmed as follows: denaturation at 95°C for 3 min, 
annealing for 36 sec, extension at 72°C for 60 sec, followed by 10 min at 72°C for 
final extension. The optimized annealing temperatures and optimal number of cycles 
for each primer are as follows. 
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Primer Sequence (5, — 3’） Annealing Optimal Product 
temperature no. of size 
cycles 
P2-adrenoceptor 58°C 34 329 bp 
• Forward G C C T G C T G A C C A A 
G A A T A A G G C C 
Reverse C C C A T C C T G C T C C A 
C C T 
(^-adrenoceptor 58°C 34 380 bp 
Forward C C A C G G T G G G A G G 
C A A C C 
Reverse C T G G C T C A T G A T G G 
G C G C 
P" a c t i n 60°C 26 516 bp 
Forward C A A C G G C T C C G G C A 
T G T G C A 
Reverse C C G G C C A G C C A G G 
T C C A G A C 
2.2.2.2.5. Agarose gel electrophoresis 
The P C R products were analyzed by 1% agarose gel containing 1 ^ g/ml ethidium 
bromide. 5 pi P C R sample was mixed with 1 |il 6X gel loading dye. The mixture 
was subjected to electrophoresis in IX T A E buffer on the 1 % agarose gel at a 
constant voltage of 120V for 30 min. Fluorescence signal from gene expression was 
visualized under U V light and captured by UVI™Photo (UVI Tech., Warwickshire, 
UK). ‘ 
2.2.2.2.6. Data representation and analysis 
The band intensity was measured by U V I ™ B a n d Windows Application (UVI Tech., 
Warwickshire, U K ) and was expressed as an arbitrary unit normalized against 
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corresponding control p-actin value. Data are expressed as means 士 S.E.M. and 
analyzed by Student's t-test and one-way A N O V A with post hoc Bonferroni's 
correction for multiple comparisons using GraphPad Prism (San Diego, CA, USA). 
Difference was considered to be statistically significant at P <0.05. 
2.2.2.3. Western blotting 
Western blotting was performed as described previously (Lam et al., 2006) with 
minor modifications. Details are as follow. 
2.2.2.3.1. Tissue preparation 
Abdominal (omental) adipose tissues were harvested from +m/+db and +db/+db 
mice immediately after being sacrificed. Tissues were rinsed in ice-cold physiological 
salt solution to remove blood before subjecting to molecular biology experiments. 
2.2.2.3.2. Protein extraction 
0.3 g of sample was homogenized and lysed in 1 ml lysis buffer with the following 
composition: 50 m M Tris-HCl, 150 m M NaCl, 1 m M EDTA, 0.1% S D S and protease 
inhibitor. After incubation on ice for 30 min, the supernatant was collected by 
centrifuging the homogenate at 8000 x g for 10 min at 4。C. Protein concentration 
was determined using B C A ™ protein assay kit with B S A as standard. 
2.2.2.3.3. Western blotting 
30 |ig of protein sample per lane was loaded onto a 12% SDS-polyacrylamide gel 
electrophoresis gel. After electrophoresis (180 V, 60 min), the separated proteins 
were electrophoretically transferred to polyvinylidene difluoride membrane (12 V, 
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90 min). Nonspecific sites were blocked with 5 % non-fat dry milk for 120 min, and 
the blots were then incubated with individual antibody type: anti-(32-adrenoceptor 
antibody, 1:1000 and anti-p3-adrenoceptor antibody, 1:1000 overnight at 4。C. 
Secondary antibody including anti-rabbit H R P conjugated IgG, 1:1000; anti-mouse 
H R P conjugated IgG, 1:1000 and anti-goat H R P conjugated IgG, 1:1000 were used 
to detect binding of its corresponding primary antibody. Membranes were stripped 
by stripping buffer and re-blotted with the anti-P actin antibody, 1:10,000 to verify 
an equal loading of protein in each lane. The binding of the specific antibody was 
visualized by exposing to the photographic film after treating with Immun-Star™ 
Chemiluminescent Kit. 
2.2.2.3.4. Data representation and analysis 
T h e
 band intensity was measured by Scion Image (Scion Coporation, Frederick, M D , 
U S A ) and was expressed as an arbitrary unit normalized against corresponding 
control P-actin value. Data are expressed as means 土 S.E.M. and analyzed by 
Student's t-test and one-way A N O V A with post hoc Bonferroni's correction for 
multiple comparisons using GraphPad Prism (San Diego, CA, USA). Difference was 
considered to be statistically significant at P <0.05. 
2.3. Results 
2.3.1. Studies on the P-adrenoceptor-mediated lipolytic response in +m/+db and 
+db/+db mice 
2.3.1.1. Effect of p2-adrenoceptor agonist on lipolysis 
The responsiveness to p 2-AR agonist was assessed and compared in adipocytes 
isolated from abdominal (omental) fat depots of +m/+db and +db/+db mice. The 
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p 2-AR agonist salbutamol was used to determine the involvement of p 2-AR in the 
lipolytic response. A s depicted in Figure 2.2, the baseline lipolysis (i.e. drug-free 
conditions) observed in +m/+db mice was higher than that recorded in +db/+db 
mice (0.85 士 0.06 versus 0.29 士 0.04 ^imol glycerol/106 adipocytes, ？<0.01). 
Salbutamol stimulated lipolysis, in a concentration-dependent manner, in both 
+m/+db and +db/+db mice. The maximal response of +m/+db mice was also higher 
than that of +db/+db mice by about 4-fold (4.18 士 0.11 versus 0.99 士 0.13 pmol 
glycerol/10
6
 adipocytes, ？<0.001). 
2.3.1.2. Effect of p3-adrenoceptor agonists and their antagonists on lipolysis 
To access the role of p 3-AR subtype in lipolysis, C G P 12177A, a p 3-AR agonist (it is 
also a Pi-and p 2-AR antagonist), and B R L 37344 (a selective p 3-AR agonist) were 
used. A s shown in Figure 2.3，CGP 12177A (1 nM-1 ^iM) caused a 
concentration-dependent increase in glycerol release from adipocytes, with a greater 
magnitude of lipolysis in +m/+db mice compared to +db/+db mice (2.61 士 0.16 
versus 0.39 ± 0.05 ^ imol glycerol/10
6
 adipocytes,户<0.001). 
Similar to C G P 12177A, B R L 37344 (0.1-100 n M ) (Figure 2.4) elicited a 
concentration-dependent lipolysis in both strains of mouse, with a greater magnitude 




T o f u r t h e r
 evaluate the participation of P-AR subtype in B R L 37344-induced 
lipolysis, effects of different selective P-AR antagonists were determined. 
Adipocytes were first pretreated with the respective receptor antagonist for 30 min 
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before the administration of B R L 37344 (1 nM-1 ^iM). As depicted in Figure 2.5, 
nadolol (10 jiM, a P �/p 2-ARs antagonist) suppressed the maximal lipolytic response 
of B R L 37344 in both +m/+db and +db/+db mice by 4 2 % and 8%, respectively 
(P<0.01). Similar to nadolol, bupranolol (10 一M, a p,/p2/p3-ARs antagonist) 
significantly lowered the lipolytic response of B R L 37344 in both species (Figure 
2.6), and the maximum lipolytic response was suppressed by 4 2 % and 4 0 % in 
+m/+db mice and +db/+db mice, respectively (P<0.001 and 尸<0.01 respectively). 
ICI 118,551 (1 a (32-AR antagonist) caused a decrease in the maximal lipolytic 
response of B R L 37344 in +m/+db mice by 4 9 % (P<0.01) (Figure 2.7). SR 59230A 
(1 p M , a Ps-AR antagonist) also attenuated the maximal lipolytic response of B R L 
37344 in +m/+db mice significantly by 4 8 % (?<0.001) (Figure 2.8). 
2.3.1.3. Effect of non-selective p-adrenoceptor agonists and their antagonists on 
lipolysis 
The stimulation of lipolysis mediated through all P-AR subtypes was measured by 
using adrenaline, a non-selective (3-AR agonist (it is also an a-adrenoceptor agonist) 
secreted by the adrenal medulla and a non-selective p-AR agonist isoprenaline. 
Adrenaline (100 nM-100 p M ) caused a concentration-dependent lipolytic response in 
both species of mouse (Figure 2.9), with an attenuated maximal response observed in 
+
d b / + d b
 ^
i c e
 compared to +m/+db mice (0.76 士 0.14 versus 2.01 士 0.21 ^imol 
glycerol/10
6
 adipocytes,尸<0.001). Interestingly, on increasing concentration of 
adrenaline (+m/+db mice: 10 |iM and 100 p M , +db/+db mice: 100 j^M), 
submaximal lipolytic response occurred (at 100 juM, +m/+db mice: 0.78 土 0.22 and 
+db/+db mice: 0.19 士 0.02禪ol glycerol/106 adipocytes). In order to investigate the 
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possibility of the involvement of the 'anti-lipolytic effect' mediated through oc2-AR 
(by 100 JIM adrenaline) in this submaximal lipolytic response, oc rAR antagonist 
yohimbine (100 ^ M ) was incubated with the adipocytes for 30 min before the 
application of adrenaline (100 nM-100 ^iM). Yohimbine significantly increased the 
lipolytic response elicted by adrenaline (100 ^ M ) by 74% in +m/+db mice (P<0.01) 
(Figure 2.10). 
Isoprenaline (0.1 nM-10 ^iM) triggered lipolysis in both strains of mouse in a 
concentration-dependent fashion as shown in Figure 2.11. The maximal response of 
+m/+db mice was significantly higher than that of +db/+db mice by 4.3-fold (2.41 士 
0.38 versus 0.56 士 0.06 ^ imol glycerol/106 adipocytes, /><0.001). 
To access the contribution of p2- and p r A R subtype to lipolysis induced by 
isoprenaline, selective p-AR antagonists ICI 118,551 (0.1 and 1 p M ) and SR 59230A 
(0.1 and 1 ^ iM) were employed. Respective receptor antagonists were incubated with 
adipocytes for 30 min before the administration of isoprenaline (0.1 nM-10 (_iM). ICI 
118,551 (0.1 ^ M , a P2-AR antagonist) significantly reduced the maximal stimulation 
of glycerol release in +m/+db mice by 36% (P<0.05) (Figure 2.12). In addition, SR 
59230A (1 fxM, a p 3-AR antagonist) significantly suppressed the maximum glycerol 
release in +db/+db mice by 10% (P<0.05) (Figure 2.13). 
2.3.1.4. Effect of modulators of intracellular cyclic nucleotide monophosphate 
on lipolysis 
In order to study the downstream pathways of P-AR-mediated lipolysis, 
post-receptor agents including forskolin (a specific adenylyl cyclase activator), 
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8-bromo-cAMP (a cell permeable c A M P analogue) and dibutyryl-cGMP (a cell 
permeable c G M P analogue) were used. As shown in Figure 2.14, forskolin (10 
nM-100 j^M) induced a concentration-dependent increase in glycerol release from 
adipocytes, with a greater magnitude of lipolysis in +m/+db mice compared to 
+^b/+db mice (3.13 士 0.40 versus 0.80 士 0.14 pmol glycerol/106 adipocytes, 
尸<0.001). 8-bromo-cAMP (10 nM-100 however, could only stimulate lipolysis 
at 100 ^iM in both species (Figure 2.15). O n the other hand, dibutyryl-cGMP (0.1 
nM-100 |iM) did not induce lipolysis in both +m/+db and +db/+db mice (Figure 
2.16). 
2.3.1.5. Effect of exogenously delivered nitric oxide on lipolysis 
In an attempt to study the role of N O in lipolysis, sodium nitroprusside (SNP), an 
exogenous N O donor, was tested on isolated adipocytes. However, S N P (0.1 nM-100 
n M ) did not stimulate lipolysis in both types of mouse (Figure 2.17). 
2.3.1.6. Gene expression of p-adrenoceptors in white adipose tissue 
Gene expression of p2- (Figure 2.18 A) and p 3-AR (Figure 2.18 B) were detected in 
both types of mouse. It was revealed that there was no significant difference in 
P2-AR m R N A expression between two species (n = 3，P>0.05) (Figure 2.19). In 
contrast, the m R N A expression level of p 3-AR in +db/+db mice was about 3-fold 
lower than that observed in +m/+db mice (arbitrary units: 1.062 土 0.267 (+m/+db 
mice) versus 0.362 土 0.144 (+db/+db mice)) (n = 3，？<0.05) (Figure 2.19). 
2.3.1.7. Protein expression of p-adrenoceptors in white adipose tissue 
Protein expression of p2- (Figure 2.20 A) and (33-AR (Figure 2.20 B) were detected in 
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both types of mouse. It was found that p r A R protein expression in +db/+db mice 
(arbitrary units: 1947 士 105) was 2.4-fold lower than that in +m/+db mice (arbitrary 
units: 4714 土 1408) (n = 3, ？<0.05). In addition, the protein expression level of 
p 3-AR in +db/+db mice (arbitrary units: 1418 士 740) was 2.8-fold lower than that 
observed in +m/+db mice (arbitrary units: 3943 ± 1626) (n = 3,尸<0.05) (Figure 
2.21). 
2.3.2. Effect of folic acid treatment on lipolysis 
2.3.2.1. Determination of body weight 
A decrease in body weight (-8.5% at the end of week 4) was observed in +db/+db 
mice fed with folic acid (5.7 jug/kg and 71 昭/kg) (n = 8,尸<0.001). In contrast, there 
was no change in body weight of +m/+db mice after folic acid treatment (5.7 j^g/kg 
and 71 ^ig/kg) (n = 8，P>0.05) (Figure 2.22). Administration of folic acid did not alter 
the food consumption of all groups of mice. 
2.3.2.2. Effect of p2-adrenoceptor agonist on lipolysis 
The responsiveness of adipocytes isolated from abdominal (omental) fat depots of 
必 and +db/+db mice to p 2-AR agonist was assessed and compared after folic 
acid treatment. The p 2-AR agonist salbutamol was used to determine the involvement 
of p 2-AR in the lipolytic response. A s shown in Figure 2.23, salbutamol (100 
nM-100 fiM) stimulated lipolysis, in a concentration-dependent manner, in both 
+m/+db and +db/+db mice. In +m/+db mice, 4-week treatment of folic acid (5.7 
|ig/kg and 71 pg/kg) did not significantly alter the lipolytic response when compared 
with controls (control, 3.784 土0.333; folic acid (5.7 ^ ig/kg), 4.107 士 0.255; folic acid 
(71 fig/kg)，3.453 士 0.259 and ^imol glycerol/106 adipocytes, P>0.05). In +db/+db 
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mice，folic acid (5.7 昭/kg and 71 ^ig/kg) significantly improved the stimulatory 
effect of salbutamol on lipolysis (control, 1.549 土 0.268; folic acid (5.7 j^ g/kg), 2.641 
士 0.229 (?<0.001); folic acid (71 昭/kg), 2.211 士 0.266 (?<0.01) ^ imol glycerol/106 
adipocytes). It was also observed in +db/^db mice that the baseline glycerol release 
after folic acid treatment (5.7 ^ ig/kg and 71 吨/kg) was greater than the controls, but 
it did not reach statistical significance (control, 0.697 土 0.083; folic acid (5.7 ^ ig/kg), 
1.341 士 0.205; folic acid (71 ^ ig/kg), 0.999 士 0.156 ^ imol glycerol/106 adipocytes). 
2.3.2.3. Effect of p3-adrenoceptor agonists on lipolysis 
C G P 12177A, a selective p r A R agonist (it is also a p�-and (32-AR antagonist), and 
B R L 37344, a selective p 3-AR agonist, were used to study the participation of p 3-AR 
subtype in lipolysis. C G P 12177A (1 n M - 1 |_iM) caused a concentration-dependent 
increase in glycerol release from isolated adipocytes in both strains of mouse (Figure 
2.24). In +m/+db mice, folic acid (5.7 ^ig/kg and 71 \ig/kg) failed to alter the 
lipolytic response of C G P 12177A, as compared to their controls (control, 3.337 土 
0.351; folic acid (5.7 j_ig/kg), 3.496 士0.429; folic acid (71 jug/kg), 3.467 士 0.457 
pmol glycerol/10
6
 adipocytes, P>0.05). In contrast, in +db/+db mice, folic acid (5.7 
pg/kg but not 71 ^tg/kg) demonstrated a significant improvement in lipolytic 
response when compared with controls (control, 1.065 土 0.186; folic acid (5.7 j^ g/kg), 




O n the other hand, B R L 37344 (0.1 n M - 1 induced a concentration-dependent 
stimulatory lipolytic response in adipocytes from both strains of mouse (Figure 2.25). 
In +m/+db mice, folic acid (5.7 jig/kg but not 71 ng/kg) significantly increased the 
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maximal lipolytic response to B R L 37344 when compared with controls (control, 
3.723 士 0.378; folic acid (5.7 |ig/kg), 4.299 土 0.137 (P<0.001); folic acid (71 ^ ig/kg), 
3.615 士 0.070 (P>0.05) |_imol glycerol/106 adipocytes). In +db/+db mice, 4-week 
folic acid treatment (5.7 jag/kg and 71 ^ig/kg) significantly improved the lipolytic 
responses to B R L 37344 (control, 1.486 土（X312; folic acid (5.7 \xg/kg), 2.818 土 
0.151; folic acid (71 j^ g/kg), 2.319 土 0.390 jamol glycerol/106 adipocytes, /><0.001). 
2.3.2.4. Effect of non-selective P-adrenoceptor agonist on lipolysis 
The stimulation of lipolysis mediated through all P-AR subtypes was measured by 
using adrenaline, a non-selective p-AR agonist (it is also an a- A R agonist) secreted 
by the adrenal medulla. Adrenaline (100 nM-100 ^iM) elicited a 
concentration-dependent lipolytic response in both species of mouse (Figure 2.26). In 
+ m / + d b m i c e�lipolytic responses of adrenaline in isolated adipocytes were 
significantly increased after folic acid treatment (5.7 fig/kg and 71 pg/kg) compared 
to the control littermates (control, 2.976 士 0.360; folic acid (5.7 jig/kg), 4.167 士 
0.157 (?<0.01); folic acid (71 jag/kg), 3.463 士 0.450 (?<0.05) ^imol glycerol/106 
adipocytes). In +db/+db mice, folic acid (5.7 fxg/kg) significantly increased the 
lipolytic response of adrenaline when compared with controls (control, 1.700 士 0.158; 
folic acid (5.7 ^ig/kg) 2.514 士 0.380 |imol glycerol/106 adipocytes,尸<0.01). N o 
apparent change in the maximal lipolytic response was observed in +db/+db mice 
fed with folic acid (71 |ng/kg) (P>0.05). Interestingly, on increasing concentration of 
adrenaline, submaximal lipolytic response occurred in both strains of mouse at 100 
j iM � + m / + d b mice: control, 2.230 土 0.470; folic acid (5.7 pg/kg), 3.568 士 0.309; 
folic acid (71 —g/kg)，2.982 士 0.581 ^imol glycerol/106 adipocytes; +db/+db mice: 
control, 1.100 士 0.176; folic acid (5.7 pg/kg), 2.068 士 0.464; folic acid (71 pg/kg)， 
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1.203 士 0.402 ^ imol glycerol/106 adipocytes). 
2.3.2.5. Effect of modulators of intracellular cyclic nucleotide monophosphate 
on lipolysis 
In order to study the downstream pathways of P-AR-mediated lipolysis, 
post-receptor agents including forskolin (a specific adenylyl cyclase activator), 
8-bromo-cAMP (a cell permeable c A M P analogue) and dibutyryl-cGMP (a cell 
> 
permeable c G M P analogue) were used. Forskolin (10 nM-100 (iM) induced a 
concentration-dependent increase in glycerol release from adipocytes in both strains 
of mouse (Figure 2.27). In +m/+db mice, 4 weeks treatment with folic acid (5.7 
jig/kg and 71 M-g/kg) did not change the lipolytic response of forskolin (control, 
2.792 土 0.529; folic acid (5.7 ng/kg), 2.727 土 0.421; folic acid (71 i^g/kg), 2.174 土 
0.238 fxmol glycerol/10
6
 adipocytes,尸>0.05), whereas a significant increase in 
forskolin-induced lipolysis was observed in +db/+db mice after folic acid treatment 
(5.7 jig/kg and 71 M-g/kg) (control, 1.622 士 0.233; folic acid (5.7 昭/kg)，2.101 士 
0.145; folic acid (71 呢/kg)，2.156 ± 0.193 ^ imol glycerol/106 adipocytes,尸<0.001). 
8-bromo-cAMP (10 nM-100 ^iM) caused a moderate stimulation in lipolysis in both 
species of mouse (at 10 [iU and 100 |nM) (Figure 2.28). In +m/+db mice, there was 
no apparent change in lipolysis triggered by 8-bromo-cAMP after folic acid 
treatment (5.7 |ng/kg and 71 |ng/kg) (control, 1.668 士 0.138; folic acid (5.7 |xg/kg), 
1.972 土 0.532; folic acid (71 pg/kg), 1.288 士 0.125 ^mol glycerol/106 adipocytes, 
尸>0.05). In contrast, folic acid (5.7 |ig/kg but not 71 昭/kg) significantly improved 
the lipolytic response in +db/+db mice when compared with control mice (control, 
1.267 土 0.201; folic acid (5.7 jug/kg), 1.597 士 0.153 (尸<0.001); folic acid (71 昭/kg), 
51 
C h a p t e r 2 p -Adrenoceptors (P-ARs) 
1.409 士 0.236 (P<0.01) fimol glycerol/106 adipocytes,). 
Although the baseline lipolytic response of +m/+db and +db/+db mice was elevated, 
dibutyryl-cGMP (0.1 nM-100 ^iM) did not cause an apparent change in the baseline 
lipolysis of individual group of mice over the concentrations tested (Figure 2.29). 
2.3.2.6. Effect of exogenously delivered nitric oxide on lipolysis 
In an attempt to study the role of N O in lipolysis, sodium nitroprusside (SNP), an 
exogenous N O donor, was tested on isolated adipocytes. Despite the fact that the 
baseline lipolytic response of +m/+db and +db/+db mice was elevated, S N P (0.1 
nM—100 n M ) did not cause an apparent change in the baseline lipolysis of individual 
group of mice over the concentrations tested (Figure 2.30). 
2.3.2.7. Gene expression of P-adrenoceptors in white adipose tissue 
The modulatory effects of folic acid (5.7 |^g/kg and 71 昭/kg for 4 weeks) on the 
gene expression of p2- and (3S-AR were studied. Gene expression of (32-AR was 
detected in both types of mouse with or without folic acid treatment (Figure 2.31 A). 
In +m/+db mice, folic acid (71 ^ig/kg) significantly reduced the p 2-AR gene 
expression (?<0.01), whereas folic acid (5.7 |_ig/kg and 71 jig/kg) did not alter the 
P 2-AR gene expression in +db/+db mice (Figure 2.32 A) (P>0.05). Interestingly, the 
m R N A expression ratio of p 2-AR in +db/+db mice to +m/+db mice was actually 
increased after folic acid treatment (+m/+db: +db/+db mice: control: 1:0.630; folic 
acid (5.7 昭/kg): 1:1.060; folic acid (71 pg/kg): 1:3.748). The gene expression of 
P r A R in +m/+db mice was significantly lower than that in +db/+db mice after folic 
acid (71 jig/kg) treatment (arbitrary units: 0.317 士 0.020 (+m/+db mice) versus 
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1.189 土 0.121 (+db/+db mice))(尸<0.01) (Figure 2.32 A). 
Gene expression of p 3-AR was detected in both types of mouse with or without folic 
acid treatment (Figure 2.31 B). Folic acid (5.7 jug/kg, /><0.01 and 71 叩/kg, P<0.001) 
treatment significantly reduced the p 3-AR gene expression in +m/+db mice, but no 
significant difference was observed in +db/+db mice (P>0.05) (Figure 2.32 B). 
Similar to the trend observed for p 2-AR gene expression, the m R N A expression ratio 
of P r A R in +db/+db mice to +m/+db mice was increased after folic acid treatment 
(+m/+db: +db/+db mice: control: 1:0.551; folic acid (5.7 jug/kg): 1： 0963; folic acid 
(71 ng/kg): 1:1.636) (Figure 2.32 B). 
2.3.2.8. Protein expression of P-adrenoceptors in white adipose tissue 
The modulatory effects of folic acid (5.7 昭/kg and 71 昭/kg for 4 weeks) on the 
protein expression of p2- and (3S-AR were studied. Protein expression of (32-AR was 
detected in both types of mouse with or without folic acid treatment (Figure 2.33 A). 
Folic acid (71 叩/kg) significantly reduced the (32-AR protein expression in both 
+ m / + d b
 ^
 + d b / + d b m i c e
 (尸<0.05). p 2-AR protein expression of +m/+db mice fed 
with folic acid (71 昭/kg) was significantly lower than those fed with folic acid (5.7 
卯/kg) (P<0.05). The protein expression of p 2-AR of +db/+db mice was 
significantly lower than that of +m/+db mice after folic acid treatment (5.7 ^g/kg 
and 71 i^g/kg) (arbitrary units: folic acid (5.7 pg/kg), 0.451 士 0.020 (+m/+db mice) 
versus 0.131 士 0.065 (+db/+db mice); folic acid (71 pg/kg), 0.273 土 0.028 {+m/+db 
mice) versus 0.079 土 0.009 (+db/+db mice)) (P<0.01) (Figure 2.34 A). 
Protein expression of p 3-AR was detected in both types of mouse with or without 
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folic acid treatment (Figure 2.33 B). Folic acid treatment (5.7 [ig/kg, ？<0.01 and 71 
|ag/kg,尸<0.05) significantly increased the p 3-AR protein expression in +db/+db 
mice, but no significant difference was observed in +m/+db mice (尸>0.05) (Figure 
2.34 B). The protein expression of (33-AR of +db/+db mice was significantly higher 
than that of +m/+db mice after folic acid treatment (5.7 pg/kg and 71 jig/kg) 
(arbitrary units: folic acid (5.7 pg/kg), 0.337 士 0.129 (+m/+db mice) versus 0.731 士 
0.027 (+db/+db mice); folic acid (71 i^g/kg), 0.489 士 0.086 (+m/+db mice) versus 
0.884 士 0.135 (+db/+db mice))(尸<0.05) (Figure 2.34 B). 
2.3.3. Effect of Lingzhi (water-extract) treatment on lipolysis 
2.3.3.1. Determination of body weight 
A significant decrease in body weight (〜20% at the end of week 4) was observed 
only in +db/+db mice fed with Lingzhi (0.3 g/kg) whereas no change in body weight 
was observed in +db/+db mice fed with Lingzhi (0.03 g/kg). However, there was no 
change in body weight of +m/+db mice fed with Lingzhi (0.03 and 0.3 g/kg) (n = 5 -
6，尸<0.01) (Figure 2.35). Administration of Lingzhi did not alter the food 
consumption of all groups of mouse. 
2.3.3.2. Lipolytic effect of forskolin 
As shown in Section 2.3.1.4, forskolin was found to induce lipolysis in both species 
of mouse� Therefore, it was chosen as the lipolytic agent in this study to investigate 
the effect of Lingzhi treatment on lipolysis. 
Forskolin (10 nM-100 jiM) caused lipolysis in a concentration-dependent manner in 
both control and Lingzhi treated mice (Figure 2.36). The maximal glycerol release in 
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+m/+db mice fed with Lingzhi (0.03 g/kg and 0.3 g/kg) were not significantly 
different from that obtained from control mice (control, 2.17 士 0.40; Lingzhi (0.03 
g/kg), 2.60 士 0.68; Lingzhi (0.3 g/kg), 2.46 士 0.68 fimol glycerol/106 adipocytes, 
P>0.05). Similarly, after Lingzhi (0.03 and 0.3 g/kg) treatment, there was no 
apparent change in the maximal lipolytic response of forskolin in +db/+db mice 
(control, 2.05 士 0.21; Lingzhi (0.03 g/kg), 1.56 士 0.34; Lingzhi (0.3 g/kg), 1.56 土 
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Figure-2.2 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by salbutamol of +m/+db (〇）(n = 4) and +db/+db (•) mice (n = 4). Results 
are expressed as means 土 S.E.M. **P<0.01 and ***尸<0.001 compared to +m/+db 
mice. C: control (drug-free) condition. 
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Figure 2.3 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by C G P 12177A of +m/+db (o) (n = 5) and +db/+db (•) mice (n = 5). 
Results are expressed as means 士 S.E.M. ***P<0.001 compared to +m/+db mice. C: 
control (drug-free) condition. 
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Figure 2.4 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by B R L 37344 of +m/+db (o) (n = 5) and +db/+db (•) mice (n = 5). Results 
are expressed as means ± S.E.M. **P<0.01 and ***P<0.001 compared to +m/+db 
mice. C: control (drug-free) condition. 
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Figure 2.5 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by B R L 37344, in the absence and presence of nadolol (10 ^ iM), of +m/+db 
, a n d +db/+db mice (n = 4-5). Results are expressed as means 士 S.E.M. **尸<0.01 and 
***P<0.001 compared to the respective control. C: control (drug-free) condition. B: 
with antagonist (nadolol) alone. 
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Figure 2.6 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by B R L 37344, in the absence and presence of bupranolol (10 pM), of 
+m/+db and +db/+db mice (n = 5 for each strain of mice). Results are expressed as 
means 士 S.E.M. *尸<0.05, **P<0.01 and ***尸<0.001 compared to the respective 
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Figure 2.9 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by adrenaline of +m/+db (〇）(n = 4) and +db/+db (•) mice (n = 4). Results 
are expressed as means 士 S.E.M. *尸<0.05 and ***尸<0.001 compared to +m/+db 
mice. C: control (drug-free) condition. 
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Figure 2.10 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by adrenaline, in the absence and presence of yohimbine (100 jiM)，of 
+m/+db and +db/+db mice (n = 4 for each strain of mice). Results are expressed as 
means 土 S.E.M. **P<0.01 and ***P<0.001 compared to the respective control. C: 
control (drug-free) condition. B: with antagonist (yohimbine) alone. 
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Figure 2.11 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by isoprenaline of +m/+db (〇）(n = 4) and +db/+db (•) mice (n = 4). Results 
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Figure 2.14 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by forskolin of +m/+db (〇）(n = 4) and +db/+db (•) mice (n = 5). Results 
are expressed as means 士 S.E.M. ***户<0.001 compared to +m/+db mice. C: control 
(drug-free) condition. 
68 
Chapter 2 (3-Adrenoceptors ((3-ARs) 
3-I 
^ 令 +m/+db 
"g -S + +db/+db 




3 I 1 i ^ 
o
J
— I — I 1 1 1 1 — 
C -8 -7 -6 -5 -4 
log [8-Br-cAMP] (M) 
Figure 2.15 Concentration-response curves for the stimulation of glycerol release, 
v 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by 8-bromo-cAMP (8-Br-cAMP) of +m/+db (〇）(n = 4) and +db/+db (•) 
mice (n = 5). Results are expressed as means 土 S.E.M. C: control (drug-free) 
condition. 
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Figure.2.16 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by dibutyryl-cGMP (db-cGMP) of +m/+db (o) (n = 4) and +db/+db (•) 
mice (n = 4). Results are expressed as means 士 S.E.M. C: control (drug-free) 
condition. 
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Figure 2.17 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by sodium nitroprusside (SNP) of +m/+db (o) (n = 4) and +db/+db (•) mice 
(n = 4). Results are expressed as means 士 S.E.M. C: control (drug-free) condition. 
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Figure 2.18 Semi-quantitative RT-PCR analysis of m R N A expression levels of (A) 
(^-adrenoceptor ((32-AR), (B) p3-adrenoceptor (p3-AR) and (C) P-actin of the 
abdominal (omental) adipose tissues of +m/+db and +db/+db mice. 
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Figure 2.19 Summary of RT-PCR band intensities of m R N A determined by 
spectrophotometric analysis. Quantification of m R N A of p2-adrenoceptor (P2-AR), 
and p3-adrenoceptor (p3-AR) of the abdominal (omental) adipose tissues of +m/+db 
and +db/+db mice is normalized to p-actin for comparison. Results are expressed as 
mean (arbitrary units) 士 S.E.M. of three independent experiments. *尸<0.05 
compared to +m/+db mice. 
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Figure'2.20 Western blotting of (A) p2-adrenoceptor (|32-AR), (B) p3-adrenoceptor 
(P3-AR) and (C) P-actin protein expression of the abdominal (omental) adipose 
tissues of +m/+db and +db/+db mice. 
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Figure 2.21 Summary of p2-adrenoceptor (p2-AR) and p3-adrenoceptor (p3-AR) 
protein expression of the abdominal (omental) adipose tissues of +m/+db and 
+db/+db mice. Data (band intensity) are normalized to P-actin level. Results are 
expressed as mean (in arbitrary units) 士 S.E.M. of three independent experiments. 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 2 (3-Adrenoceptors ((3-ARs) 
w 
A / / / / / / 
^ ^ 矿 ^ 矿 
/ / / / / / , 
5 0 0 咔 — B a P ^ i i - i — — PrAR 
• ^^^Mm 5 ^U^ M^ ilfeiiMtfaudHIk；^叙JIIIIH 
身 ^ ^ ^ 
B 。 <b- ^ X s 
^ ^ / / / / 
/ / / 7 / / / / / / 
5 0 0 b p ， b ^ m m m m m 卩 一 
^ # ^ 
c ^ 4 W & ^ / / / / / / / / / / 
/ / / > x / / 旁 
5 0 0 b p — ； , 1 t ： .』丨丨麵 _•• _、丨 _丨 |響 Pectin 
Figure 2.31 Effects of folic acid (4 weeks oral gavage) (5.7 and 71 jig/kg) on the 
m R N A expression levels of (A) p2-adrenoceptor (p2-AR) and (B) p3-adrenoceptor 
(p3-AR) of the abdominal (omental) adipose tissues of +m/+db and +db/+db mice. 
(C) P-actin was measured as a loading control. 
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Figure 2.32 Summary of RT-PCR band intensities of m R N A determined by 
spectrophotometric analysis. Quantification of m R N A of (A) p2_adrenoceptor 
(P2-AR), and (B) p3-adrenoceptor (p3-AR) of the abdominal (omental) adipose 
tissues of +m/+db and +db/+db mice after folic acid treatment (4 weeks oral gavage) 
(5.7 and 71 |ag/kg) is normalized to p-actin for comparison. Results are expressed as 
mean (arbitrary units) � S.E.M. of three independent experiments. *�<0.05, 
**?<0.01 and***尸<0.001. 
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Figure 2.33 Effects of folic acid (4 weeks oral gavage) (5.7 and 71 t^g/kg) on the 
protein expression levels of (A) (32-adrenoceptor (p2-AR) and (B) p3-adrenoceptor 
(P3-AR) of the abdominal (omental) adipose tissues of +m/+db and +db/+db mice. 
(C) p-actin was measured as a loading control. 
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Figure 2.34 Summary of the protein expression of (A) (^-adrenoceptor ((32-AR) 
and (B) p3-adrenoceptor ((33-AR) of the abdominal (omental) adipose tissues of 
+m/+db and +db/+db mice after folic acid treatment (4 weeks oral gavage) (5.7 and 
71 |ag/kg). Data (band intensity) are normalized to P-actin level. Results are 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Peroxisome Proliferator-Activated Receptor-y (PPAR-y) 
3. Peroxisome Proliferator-Activated Receptor-y (PPAR-y) 
3.1. Introduction 
3.1.1. Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors and belong to the nuclear receptor superfamily (Blaschke et al., 
2006). They regulate transcription of target genes by forming heterodimers with the 
retinoid X receptor (RXR) and binding to specific P P A R response elements (PPREs) 
in the promoter region of target genes (Gearing et al., 1993). Three isoforms, which 
are encoded by separate genes, have been identified: PPAR-a, PPAR-y and PPAR-5 
(Kersten, 2002). PPAR-a and PPAR-y are predominantly present in liver and adipose 
tissue, respectively, whereas PPAR-5 is ubiquitiously expressed (Michalik et al., 
2002). 
3.1.1.1. Peroxisome proliferator-activated receptor-y 
Peroxisome proliferator-activated receptor-y (PPAR-y) is expressed in adipocytes, 
intestinal cells and macrophages (Kahn et al., 2000). Three isoforms of PPAR-y have 
been identified, namely PPAR-y 1, PPAR-y2 and PPAR-y3 (Blaschke et al., 2006). 
Proteins produced from PPAR-y2 contain an additional NH2-terminal region, 
composed of 30 amino acids，whereas proteins derived from PPAR-y 1 and PPAR-y3 
m R N A are identical (Desvergne et al., 1999). 
3.1.1.1.1. PPAR-y in obesity, lipid metabolism and type 2 diabetes 
Recent evidence suggested that PPAR-y activation has an important role in the 
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regulation of energy metabolism, thus there is an increasing interest in the potential 
connection between PPARs and obesity (Kersten, 2002). Expressed at high levels in 
adipose tissue, PPAR-y is a central regulator of adipocyte gene expression and 
differentiation (Tontonoz et al., 1994). Studies demonstrated that PPAR-y has an 
essential role in promoting adipogenesis both in vivo and in vitro (Rosen et al., 1999). 
A gene mutation encoding for PPAR-y has been suggested associated with extreme 
obesity (Freake, 1999). In over-weight patients, the basal expression of PPAR-y is 
not altered, and a defect in PPAR-y functions has been suggested for the development 
of body fatness (Rieusset et al., 1999). Consistent with these findings, humans with 
dominant-negative mutations in PPAR-y manifest partial lipodystrophy and severe 
peripheral and hepatic insulin resistance because of increased triglyceride and fatty 
acid deposition into skeletal muscle and liver (Savage et a!., 2003). 
3.L1.1.2. PPAR-y in inflammation and atherosclerosis 
PPAR-y is expressed in vascular smooth muscle cells (Marx et al, 1998), endothelial 
cells (Marx et al., 2000)，macrophages (Ricote et al., 1998), and T-cells (Jiang et al., 
1998), where it plays an important role in the regulation of inflammatory responses. 
It has been demonstrated that PPAR-y-specific ligand (troglitazone) can inhibit the 
production of a host of inflammatory cytokines, such as tumour necrosis factor-a 
(TNF-a), interleukin- (IL) 1(3 and IL-6 in monocytes (Jiang et al., 1998), matrix 
metalloproteinase 9 in macrophages (Ricote et al, 1998) or endothelin-1 (Delerive et 
al, 1999) and IFN-inducible protein 10 in endothelial cells (Delerive et al., 1999; 
Marx et al., 2000). Activation of PPAR-y resulted in an in vitro vascular relaxation 
and a decrease in blood pressure of in hypertensive mice (Ryan et al, 2004). In 
various studies, PPAR-y ligands have been shown to decrease atherosclerotic lesion 
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formation in genetically prone mouse models (Blaschke et al., 2006). Interestingly, 
ligands to the heterodimeric partners of PPAR-y, R X R , also attenuated 
atherosclerosis (Claudel et al., 2001). These vascular relaxation effects of PPAR-y 
agonists in different tissues of normal animals have been suggested involving various 
ion channels gatings modulation (Knock et al., 1999). 
3.1.1.2. PPAR-y and thiazolidinediones 
A s briefly introduced in Section 1.5.2.4, thiazolidinediones (TZDs) are insulin 
sensitizers through the activation of PPAR-y. T Z D s reduce peripheral insulin 
resistance characteristics of patients with type 2 diabetes mellitus (T2DM) (Saltiel et 
al, 1996). This effect results in increased peripheral glucose use (Lehmann et al, 
1995)，reduced hepatic glucose output (Stumvoll et cd., 1995), and consequently, 
improvement in overall glycemic control. Apart from the effects on carbohydrate 
metabolism, there are also beneficial effects on plasma lipids - both pioglitazone and 
rosiglitazone increase serum levels of H D L (van Wijk et al., 2003), while pioglitzone 
is also associated with a marked reduction in plasma triglyceride levels (Khan et al., 
2002). 
PPAR-y exists as heterodimer with R X R and binds to P P R E within the promoter 
domains of target genes (Stumvoll et al.，2001). W h e n T Z D binds to PPAR-y, a 
corepressor complex dissociates and a coactivator complex, containing histone 
acetylase activity, is recruited to the heterodimer (Moneva et al., 2002). This 
facilitates active gene transcription (Figure 3.1). For instance, one of the target genes 
for PPAR-Y is perilipin (Dalen et al., 2004). Treatment of differentiating 3T3-L1 
adipocytes with PPAR-y agonist increased perilipin gene expression (Moneva et al., 
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2002). PPAR-y activation promotes differentiation of adipocytes and induction of 
lipogenic and glucoregulatory proteins (Kahn et al., 2000). TZDs induce lipoprotein 
lipase, thereby boosting triglyceride uptake into fat, and reducing circulating free 
fatty acids (Moneva et al., 2002). The insulin sensitizing effect of TZDs may also be 
mediated by a decline in circulating free fatty acids level, adipocyte TNF-a and 
changes in resistin expression (Kahn et al., 2000). 
iJ^ i 、 ： … … 
N j C t e j S
 ‘
 f 广 - U r ^ ^ 1 
wxw /
 R N A 
T?D aL^rre fit DNA 
Figure 3.1 Cellular mechanism of the action of thiazolidinediones (TZDs). Ins, 
insulin; IR, insulin receptor; PPARy, peroxisome proliferators-activated receptor; 
RXR, retinoid X receptor. (Adopted from Stumvoll et al., 2001) 
It has been reported that rosiglitazone failed to reduce glucose or insulin levels in 
mice which lack white adipose tissue (Chao et al., 2000). In addition, expression and 
secretion of adiponectin, a hormone exclusively produced by the adipose tissue, is 
increased in the presence of PPAR-y ligands (troglitazone, pioglitazone and 
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rosiglitazone) (Maeda et al., 2001), suggesting that white adipose tissue is a primary 
target of PPAR-y ligands. However, in other recent studies using different mouse 
models lacking adipose tissue, TZDs were found to improve insulin sensitivity, 
indicating a beneficial effect outside the adipose tissue (Burant et al., 1997; Kim et 
al., 2003). Selective deletion of PPAR-y in the skeletal muscle and liver in mice 
results in severe whole body insulin resistance (Gavrilova et al., 2003; Hevener et al., 
2003). These observations imply the multiple tissue targets of TZDs. 
3.2. Materials and method 
3.2.1. Materials 
3.2.1.1. Composition of physiological salt solution 
Physiological salt solution was prepared as described in Section 2.2.1.1. 
3.2.1.2. Materials used in lipolysis experiment 





3.2.1.3. Materials used in RT-PCR 
Materials used are as listed in Section 2.2.1.3. 
3.2.1.4. Materials used in Western blotting 
Materials used are as listed in Section 2.2.1.4. Anti-PPAR-y antibody was purchased 
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from Santa Cruz Biotechnology. 
3.2.2. Methods 
3.2.2.1. Lipolysis experiment 
Abdominal (omental) adipocytes were isolated as described in Section 2.2.2.1.3. 
Lipolysis measurement was done as described in Section 2.2.2.1.4, with one of the 
following PPAR-y agonists: ciglitazone, pioglitazone and troglitazone (10 nM-10 
jiM). Data analysis was done as described in Section 2.2.2.1.5. 
3.2.2.2. RT-PCR 
Abdominal (omental) adipose tissue was prepared as described in Section 2.2.2.2.1. 
R N A extraction and RT-PCR were performed as described in Section 2.2.2.2.2 -
2.2.2.2.4. The optimized annealing temperatures and optimal number of cycles for 
the primers used are as follows. 
Primer Sequence 3') Annealing Optimal Product 
temperature no. of size 
cycles 
PPAR-y 58°C ~28 527 bp 
Forward G G C G A G G G C G A T C T T G A C 
A G 
Reverse A G C A G G T T G T C T T G G A T G 
T 
P-actin 60°C 26 516 bp 
Forward C A A C G G C T C C G G C A T G T G 
C A 
Reverse C C G G C C A G C C A G G T C C A G 
A C 
Gel electrophoresis and data analysis were performed as described in Section 
2.2.2.2.5 and 2.2.2.2.6. 
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3.2.2.3. Western blotting 
Abdominal (omental) adipose tissue was prepared as described in Section 2.2.2.3.1. 
Protein extraction and Western blotting were performed as described in Section 
22.2.3.2 and 2.2.2.3.3. Primary and secondary antibodies used were anti-PPAR-y 
antibody, 1:1000 and anti-goat H R P conjugated IgG, 1:1000 respectively. Data 
analysis was performed as described in Section 2.2.2.3.4. 
3.3. Results 
3.3.1. Effect of PPAR-y agonists on lipolysis 
Three PPAR-y agonists (ciglitazone, pioglitazone and troglitazone) (10 nM-10 jiM) 
were evaluated on the lipolytic response of the abdominal (omental) adipocytes. 
However，all three PPAR-y agonists tested failed to alter the baseline lipolysis in both 
+m/+db and +db/+db mice (Figure 3.2- 3.4). 
3.3.2. Gene expression of PPAR-y in white adipose tissue 
Gene expression of PPAR-y was detected in both types of mouse (Figure 3.5). 
' H o w e v e r , there was no difference in PPAR-y m R N A expression in the white 
abdominal adipose tissues (arbitrary units: 1.318 士 0.025 (+m/+db mice) versus 
1.232 土 0.060 (+db/+db mice)) (?>0.05) (Figure 3.6). 
3.3.3. Protein expression of PPAR-y in white adipose tissue 
Protein expression of PPAR-y was detected in both types of mouse (Figure 3.7). 
There was no apparent difference in PPAR-y protein expression in the white 
abdominal adipose tissues (arbitrary units: 3888 士 405 (+m/+db mice) versus 2335 士 
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Figure 3.2 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by ciglitazone of +m/+db (〇）(n = 4) and +db/+db (•) mice (n = 4). Results 
are expressed as means 士 S.E.M. C: control (drug-free) condition. 
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Figure 3.3 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by pioglitazone of +m/+db (0) (n = 4) and +db/+db (•) mice (n = 4). 
Results are expressed as means 土 S.E.M. C: control (drug-free) condition. 
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Figure 3.4 Concentration-response curves for the stimulation of glycerol release, 
as a measure of the lipolytic response, from the abdominal (omental) adipocytes 
elicited by troglitazone of +m/+db (〇）(n = 4) and +db/+db (•) mice (n = 4). Results 
are expressed as means ± S.E.M. C: control (drug-free) condition. 
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Figure 3.5 Semi-quantitative RT-PCR analysis of m R N A expression levels of (A) 
PPAR-y and (B) p-actin of the abdominal (omental) adipose tissues of +m/+db and 
+db/+db mice. 
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Figure 3.6 Summary of RT-PCR band intensities of m R N A determined by 
spectrophotometric analysis. Quantification of m R N A of PPAR-y of the abdominal 
(omental) adipose tissues of +m/+db and +db/+db mice is normalized to |3-actin for 
comparison. Results are expressed as mean (arbitrary units) 土 S.E.M. of three 
independent experiments. 
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Figure 3.7 Western blotting of (A) PPAR-y and (B) P-actin protein expression of 
the abdominal (omental) adipose tissues of +m/+db and +db/+db mice. 
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Figure 3.8 Summary of PPAR-y protein expression of the abdominal (omental) 
adipose tissues of +m/+db and +db/+db mice. Data (band intensity) are normalized 
to P-actin level. Results are expressed as mean (in arbitrary units) 士 S.E.M. of three 
independent experiments. 
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4. 3-Hydoxy-3-Methylglutaryl Coenzyme A (HMG-CoA) 
Reductase 
4.1. Introduction 
4.1.1. Cholesterol metabolism and cardiovascular diseases 
Hypercholesterolemia plays a crucial role in the development of atherosclerotic 
disease (Feingold et al, 1994) and coronary heart disease (CHD) (Asztalos et al., 
2002). The risk for C H D increases progressively with increasing levels of total serum 
cholesterol or L D L cholesterol on the individual level (Lennernas et a!., 1997). O n 
the other hand, a central feature of the disordered metabolism present in type 2 
diabetes mellitus (T2DM) is dyslipidemia (Reaven, 1988), which is characterized by 
elevated levels of triglycerides, low levels of H D L cholesterol, and small dense L D L 
particles with normal or slightly elevated L D L cholesterol levels (Ginsberg, 1991). 
It is well known that 3-hydoxy-3-methylglutaryl Coenzyme A (HMG-CoA) 
reductase, which converts H M G - C o A to mevalonate, is the rate-limiting enzyme 
embedded in the endoplasmic reticulum, responsible for the endogenous cholesterol 
synthesis in the liver and intestine (Faust et al., 1980; Feingold et al, 1994). A group 
of lipid-lowering drugs, which alleviate the problems arising from dyslipidemia by 
interfering with the cholesterol biosynthetic pathway, are available 一 statins. 
4.1.2. Statins 
Statins are reversible inhibitors of the microsomal enzyme H M G - C o A reductase 
(Feingold et al., 1994), and thereby they can suppress cholesterol biosynthesis 
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(Grundy, 1988). Back to the 1970s, Dr. Endo and colleagues reported the discovery 
of mevastain, the first statin drug derived from fungi (Endo et al., 1976). To date, 
there are seven statins available: lovastatin, simvastatin, pravastatin, fluvastatin, 
atorvastatin, rosuvastatin and pitavastatin (Asztalos et al., 2002; Steinmetz, 2002). 
First-generation statins, such as lovastatin and mevastatin, were isolated from fungi 
(Endo et al., 1976) while second- and third-generation statins have been developed 
by either modification of first-generation statins (Lennernas et a!., 1997) or chemical 
synthesis in the laboratory (Pahan, 2006). 
4.1.2.1. Modes of action 
Statins are structural analogues of H M G - C o A and thus inhibit H M G - C o A reductase 
competitively with an affinity about 1000-10000 times greater than that of the natural 
substrate (Pahan, 2006). They directly inhibit the cholesterol synthesis in liver 
(Feingold et al., 1994). Such a decrease in intracellular cholesterol levels results in 
an upregulated production of microsomal H M G - C o A reductase and the translocation 
of L D L receptors to cell surface (Grundy, 1988). Consequently, additional cholesterol 
is provided to the cell by de novo synthesis and by receptor-mediated uptake of L D L 
cholesterol from the blood (Lennernas et al., 1997). W h e n this happens in 
extrahepatic cells, the net cholesterol balance is not altered as they cannot break 
down cholesterol (Sirtori, 1993). However, the liver cell possesses the enzyme 
7a-hydroxylase which breaks down cholesterol to bile salts for excretion (Sirtori, 
1993). In addition to the direct inhibition of cholesterol synthesis, statins also 
upregulate the expression of L D L receptors in the liver cell, and this in turn leads to 
an increased uptake of cholesterol and production of bile salts (Lennernas et al, 
‘1997). As a result, a net loss of cholesterol is obtained. 
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Apart from the well known inhibition effect on cholesterol biosynthesis, statins also 
display cholesterol-independent (pleiotropic) effects (Brown et al., 1986; Ridker et 
al., 1999). For example, inhibition of small G protein activation (Pahan, 2006); 
suppression of proinflammatory molecules including tumour necrosis factor-a 
(TNF-a), interleukin- (IL)lp and IL-6 (Pahan et al., 1997); stimulation of endothelial 
nitric oxide synthase (Hernandez-Perera et al., 1998); inhibition of smooth muscle 
cell proliferation (Laufs et al., 1999); inhibition of reactive oxygen species (ROS) 
production (Pahan, 2006) and new blood vessel formation (Weiss et al., 2002). 
4.1.2.2. Therapeutic efficacy of statins 
4.1.2.2.1. Diabetes 
It has been documented that type 2 diabetics have an atherogenic lipid profile which 
greatly raises the risk of C H D (Ginsberg, 1991). In clinical trials, routine use of 
fluvastatin in patients with T 2 D M led to a 47% reduction in the relative risk of 
cardiac death (Scuffham et al, 2005). A n increased oxidative stress has been 
suggested to contribute to the occurrence of atherosclerosis and other problems in 
diabetic patients (Pahan, 2006). It has been shown that the administration of 
pitavastatin in streptozotocin-induced diabetic rats attenuated the increased oxidative 
stress to control levels (Tsubouchi et al., 2005). Apart from C H D , it is known that 
peripheral neuropathy is a frequent and major complication of diabetes (Chorzempa, 
2006). Interestingly, rosuvastatin restored nerve vascularity in type 2 diabetic mice 
by the stimulation of neuronal nitric oxide synthase (nNOS) in sciatic nerves (Ii et al., 
2005). Therefore, statins possess their therapeutic values in diabetes not only by 
modulating the lipid profile, but also through their pleiotropic effects. 
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4.1.2.2.2. Coronary artery disease 
In addition to cholesterol-lowering effects, statins seem to ameliorate multiple 
problems in patients with atherosclerosis (O'Driscoll et al., 1997). Increasing 
evidence shows that inflammation and the underlying cellular and molecular 
mechanisms are responsible for the progression of atherosclerosis (Rosenson et aL, 
2003). In fact, the association of statins use and survival was found to be markedly 
influenced by the inflammatory status of the patient, suggesting the alleviation of 
vascular inflammation or attenuation of inflammatory activity m a y be an important 
mechanism by which statins exhibit improvement in survival (Schillinger et al., 
2004). Apart from the cholesterol-lowering and anti-inflammatory activities, the 
improvement of endothelial function and plaque stabilization may also be involved in 
the therapeutic effects in coronary artery disease by statins (Pahan, 2006). 
4.1.3. Distribution and expression of HMG-CoA reductase 
Apparently, the liver is the target organ for the statins due to the fact that it is the 
major site of cholesterol biosynthesis, lipoprotein production and L D L catabolism 
(Brown et al., 1986). At the same time, H M G - C o A reductase is also required in 
extrahepatic tissues for cholesterol biosynthesis so as to maintain normal cell 
functions. The significance of the involvement of H M G - C o A reductase in the 
functions in various internal organs (e.g. kidneys (Agarwal, 2006), lungs (Ii et al., 
2005); heart (Cirrincione et al., 2006) and brain (Meske et al., 2003)) has been 
reported. The existence of extrahepatic H M G - C o A reductase m a y account for the 
pleiotropic effects of statin in various biological systems. 
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4.2. Materials and method 
4.2.1. Materials 
4.2.1.1. Composition of physiological salt solution 
Physiological salt solution was prepared as described in Section 2.2.1.1. 
4.2.1.2. Materials used in lipolysis experiment 







 (prepared from simvastatin using sodium Tocris-Cookson 
hydroxide in ethanol) 
4.2.1.3. Materials used in RT-PCR 
Materials used are as listed in Section 2.2.1.3. 
4.2.1.4. Materials used in Western blotting 
Materials used are as listed in Section 2.2.1.4. Anti-HMG-CoA reductase antibody 
was purchased from Upstate (USA). 
4.2.2. Methods 
4.2.2.1. Lipolysis experiment 
Abdominal (omental) adipocytes were isolated as described in Section 2.2.2.1.3. 
Lipolysis measurement was done as described in Section 2.2.2.1.4, with one of the 
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following statins: simvastatin, simvastatin N a
+
 and pravastatin (1 nM-100 p.M). Data 
analysis was done as described in Section 2.2.2.1.5. 
4.2.2.2. RT-PCR 
Different internal organs (liver, heart, lungs, brain, skeletal muscle, kidneys and 
abdominal fat tissues) were prepared as described in Section 2.2.2.2.1. R N A 
extraction and RT-PCR were performed as described in Section 2.2.2.2.2 - 2.2.2.2.4. 
The optimized annealing temperatures and optimal number of cycles for the primers 
used are as follows. 
Primer Sequence (5' —> 3') Annealing Optimal Product 
temperature no. of size 
cycles 
H M G - C o A 55°C 35 356 bp 
reductase 
Forward C G G T G C A T C G C C A T C C 
T G T A C 
Reverse A C G C C T G A C A T G G T G 
C C A A C T C 
P-actin 60°C 26 516 bp 
Forward C A A C G G C T C C G G C A T ‘ 
G T G C A 
Reverse C C G G C C A G C C A G G T C 
C A G A C 
Gel electrophoresis and data analysis were performed as described in Section 
2.2.2.2.5 and 2.2.2.2.6. 
4.2.2.3. Western blotting 
.Different internal organs (liver, heart, lungs, brain, skeletal muscle, kidneys and 
abdominal fat tissues) were prepared as described in Section 2.2.2.3.1. Protein 
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extraction and Western blotting were performed as described in Section 2.2.2.3.2 and 
2.2.2.3.3. Primary and secondary antibodies used were anti-HMG-CoA reductase 
antibody, 1:1000 and anti-rabbit H R P conjugated IgG, 1:1000 respectively. Data 
analysis was performed as described in Section 2.2.2.3.4. 
4.3. Results 
4.3.1. Effect of statins on lipolysis 
Three statins (simvastatin (hydrophobic and membrane permeable), simvastatin N a
+ 
(salt form of simvastatin, hydrophilic and membrane impermeable) and pravastatin 
(hydrophilic, membrane impermeable)) (1 nM-100 p,M) were evaluated on the 
lipolysis response of the abdominal (omental) adipocytes. However, all three statins 
tested failed to alter the baseline lipolysis in both +m/+db and +db/+db mice (Figure 
4.1-4.3). 
4.3.2. Gene expression of HMG-CoA reductase in various internal organs 
The level of H M G - C o A reductase detected in the liver, which is a major organ 
involved in the endogenous cholesterol synthesis, was employed as the reference for 
comparison. The existence, if any, of this enzyme in other internal organs was 
determined. In +m/+db mice, all internal organs tested (heart, lungs, brain, skeletal 
muscle, kidneys and abdominal fat) demonstrated the presence of H M G - C o A 
reductase (Figure 4.4). Compared to liver, the m R N A expression of H M G - C o A 
reductase detected in heart and abdominal fat was significantly lower (尸<0.001) 
(Figure 4.5). 
Similarly, H M G - C o A reductase was present in all internal organs tested in +db/+db 
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mice (Figure 4.4). However, in contrast, a lower m R N A expression of H M G - C o A 
reductase was observed in the brain (尸<0.05), heart, lungs, skeletal muscle and 
abdominal fat tissues (P <0.001) (Figure 4.5.), whereas no apparent difference in the 
expression was observed in kidneys, compared to the liver (P〉0.05). 
To evaluate the influence of obese/diabetic conditions, the m R N A expression of 
H M G - C o A reductase of +m/+db and +db/+db mice was compared. In all organs 
examined, except the lungs and skeletal muscle, there was no difference in the 
expression of H M G - C o A reductase of the same internal organ between +m/+db and 
+db/+db mice. Interestingly, the m R N A expression of H M G - C o A reductase of the 
lungs and skeletal muscle of +db/+db mice was significantly lower 3.5-fold as 
was detected in +m/+db mice) than that observed in +m/+db mice (尸<0.01) (Figure 
4.5). 
4.3.3. Protein expression of HMG-CoA reductase in various internal organs 
To further demonstrate the existence of H M G - C o A reductase in different internal 
organs，Western blots analysis was performed. In +m/+db mice, all organs, except the 
abdominal fat tissue, demonstrated the existence of H M G - C o A reductase (Figure 
4.6). The protein expression of H M G - C o A reductase observed in the lungs and 
kidneys was significantly higher than that in the liver (尸<0.01) (Figure 4.7). In 
contrast, there was only a minimal protein expression of H M G - C o A reductase in the 
abdominal fat tissues (Figure 4.6). In +db/+db mice, a similar trend of protein 
expression of H M G - C o A reductase of all organs examined was found, as observed in 
+m/+db mice (Figure 4.7). 
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Similar to the m R N A expression, a differential protein expression of H M G - C o A 
reductase in different organs of +m/+db and +db/+db mice was detected. However, 
in the same internal organ of both mice species, there was no apparent difference in 
the protein expression of H M G - C o A reductase (P>0.05) (Figure 4.7). 
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Figure 4.1 Concentration-response curves for stimulation of glycerol release, as a 
measure of the lipolytic response, from the abdominal (omental) adipocytes elicited 
by simvastatin of +m/+db (o) (n = 4) and +db/+db (•) mice (n = 4). Results are 
expressed as means 土 S.E.M. C: control (drug-free) condition. 
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Figure 4.2 Concentration-response curves for stimulation of glycerol release, as a 
measure of the lipolytic response, from the abdominal (omental) adipocytes elicited 
by simvastatin Na+ of +m/+db (〇)(n = 4) and +db/+db (•) mice (n = 4). Results are 
expressed as means 士 S.E.M. C: control (drug-free) condition. 
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Figure 4.3 Concentration-response curves for stimulation of glycerol release, as a 
measure of the lipolytic response, from the abdominal (omental) adipocytes elicited 
by pravastatin of +m/+db (〇)(n = 4) and +db/+db (•) mice (n = 4). Results are 
expressed as means 士 S.E.M. C: control (drug-free) condition. 
117 
Chapter 4 3-Hydoxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase 
身 、 身 、 身 、 / 、 於 妒 
/ / / / 一 / / / 
bp —• ^ ^ j i m m j u p m i m u m 
― � ； r e d u c t a s e 
" 、 / V 6 V 6 V / / . 
bp —• E ^ p B f p m i ^ B R m ^ f l H m 
r e d u c t a s e 
500 bp — • p j * | i .,r ！：；^!1 “ H 1 P-actin 
Figure 4.4 Semi-quantitative RT-PCR analysis of m R N A expression levels of 
H M G - C o A reductase and P-actin of the same internal organs of +m/+db mice and 
+db/+db mice. 
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Figure 4.5 Summary of R T - P C R band intensities of m R N A determined by 
spectrophotometric analysis. Quantification of m R N A of H M G - C o A reductase is 
normalized to p-actin m R N A for comparison. Results are expressed as mean 
(arbitrary units) 土 S.E.M. of three independent experiments. *尸<0.05, **/><0.01 and 
* * */
>
<0.001 compared to respective control mice. 
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Figure 4.6 Western blotting of H M G - C o A reductase and p-actin protein 
expression of the same internal organs of +m/+db and +db/+db mice. 
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Figure 4.7 Summary of H M G - C o A reductase protein expression of the same 
internal organs of +m/+db and +db/+db mice. Data (band intensity) are normalized 
to p-actin content. Results are expressed as mean (in arbitrary units) 士 S.E.M. of 
three independent experiments. 
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5. Discussion 
The prevalence of obesity and diabetes has increased considerably in recent decades 
in our modern society. Health problems associated with these pandemics include a 
wide range of cardiovascular diseases (Frayn, 2005). Aberration of lipid metabolism 
is known to be one of the important factors in the development of obesity and 
diabetes. Since adipose tissue lipolysis plays a pivotal role in controlling the quantity 
of triglycerides stored in fat depots and in determining the plasma free fatty acid 
level, understanding its critical steps can be one of the strategies to cope with obesity 
and diabetes. 
5.1. p-adrenoceptor-mediated lipolysis 
It is well established that there is an increased circulating free fatty acid level 
observed in obese subjects (Blaak, 2003), however, problems exist in ascertaining the 
denominator to express lipolysis, as introduced in Section 1.3.2. It has been 
suggested that it is preferable to express free fatty acid or glycerol release in terms of 
lean body mass when the purpose is to determine lipid mobilization in satisfying 
energy needs, due to the fact that lean body mass correlates strongly with total 
energy expenditure at rest (Ravussin et al., 1986). In contrast, as the present study 
attempted to examine the mechanisms and regulation of lipolysis, data should be 
expressed in terms of fat. In order to ensure a fair comparison, the lipolytic activity 
was measured in terms of fat cell number, which was also used in other similar 
studies on lipolysis in rodents (Germack et al., 2000; Llado et al., 2000). 
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Although there is an augmented delivery of free fatty acid into the circulation in 
obese subjects, this increase is not always particularly marked when compared with 
lean subjects. It was not even significant in a study in which the net rate of baseline 
lipolysis was measured in obese and non-obese human subjects (Riemens et al., 
2000). In the present study, there was a 〜3-fold higher baseline lipolysis in isolated 
omental adipocytes of +m/+db mice compared to that of +db/+db mice. Consistent 
with previous reports, a lower resting lipolysis was detected in the adipose tissue of 
obese m e n by microdialysis (Engeli et al., 2007) and primary human adipocyte 
culture (Langin et al., 2005). The lowered baseline lipolysis in +db/+db mice can be 
attributed to the down-regulated adipose triglyceride lipase (ATGL) m R N A level, 
which paralleled the findings that A T G L expression level ( m R N A and protein) was 
reduced in overweight-obese patients showing insulin resistance (Jocken et al., 
2007b). Indeed, A T G L has been suggested as a major enzyme mediating the 
hydrolysis of triglycerides during basal lipolysis (Langin et al., 2005). Thus, the 
reduced A T G L expression m a y contribute to the triglyceride accumulation in adipose 
tissue, causing the development of obesity in +db/+db mice (Villena et al., 2004). 
This can also be interpreted that this down-regulated lipolytic rate in the +db/+db 
mice m a y be a physiologically reasonable remedy of the body to prevent the 
production of excess free fatty acids into the circulation, as suggested by Frayn 
(Frayn, 2005). 
P-adrenoceptors (P-ARs) have been shown to be present in adipocytes, and the 
activation of (32- and p 3-AR results in lipolysis (Arner, 2005; Carmen et al., 2006; 
Langin, 2006). In order to evaluate the role and the underlying mechanisms involved 
in the p-AR-mediated lipolysis under diabetic/obese conditions, a range of p - A R 
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agonists were used: salbutamol (a selective P2-AR agonist) (Louis et al., 2000), C G P 
12177A (a selective p 3-AR agonist) (Galitzky et al., 1997), B R L 37344, (selective 
P 3 - A R agonist) (Germack et al., 1997), adrenaline and isoprenaline (both are 
non-selective P-AR agonists) (Germack et al., 1997). In the present study, it was 
demonstrated that the p 2-AR agonist salbutamol elicited a concentration-dependent 
lipolytic response in isolated omental adipocytes of both +m/+db and +db/+db mice. 
It is consistent with a previous study in which activation of p 2 - A R by salbutamol and 
formoterol induced lipolysis in epididymal white adipocytes from Sprague-Dawley 
rats (Louis et al., 2000). In type 1 diabetes mellitus ( T 1 D M ) patients, local perfusion 
of selective P2-AR agonist terbutaline in situ caused similar glycerol release from 
adipose tissue and muscle compared to control subjects, and the reduced lipolysis 
during mild-moderate hypoglycemia in these patients was attributed to a deficiency 
in catecholamines release rather than an impaired sensitivity (Enoksson et al., 2003). 
In contrast, in our type 2 diabetes mellitus ( T 2 D M ) animal model +db/+db mice, the 
maximal lipolytic response to salbutamol was blunted (over the same concentration 
range as in previous report by Louis et al, 2000), implying an impairment in 
lipolytic response upon p 2 - A R activation. Perhaps, it m a y explain the accumulation 
of abdominal adipose tissue under the influence of T 2 D M was possibly due to a 
decreased sensitivity to P2-AR activation. 
P 3 - A R agonists have been suggested to improve obesity and metabolic disorders in 
rodents (Hashimoto et al., 1996) and human (de Souza et al, 2001). Oral 
administration of the p 3-AR agonist B R L 35135A (0.05 mg/kg/day, 6 weeks) resulted 
in the reduction of the visceral white fat weight/total energy intake ratio in Zucker 
f a / f a rats (Hashimoto et al., 1996) while daily administration of B R L 35135A (0.5 
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and 5 mg/kg/day, 4 weeks) improved hyperglycemia in +db/+db mice (Hashimoto et 
al., 1996). The present data showed that lipolysis was stimulated by the P3-AR 
agonists C G P 12177A and B R L 37344 in omental adipocytes of +m/+db and 
+db/+db mice in a concentration-dependent manner, which is in accordance with 
previous reports in which these p 3 - A R agonists caused lipolytic effects in isolated 
epidydymal adipocytes from Sprague-Dawley rats (Canova et al, 2005; Carmen et 
al., 2006; Germack et al., 2000; Germack et al., 1997). Again, a significant yet 
attenuated maximal lipolytic response was observed in +db/+db mice, which agreed 
with previous study that an acute CL-316243 (a p 3-AR agonist) application elicited a 
free fatty acid release from lipolysis in type 2 non-obese diabetic M K R mice, though 
weaker compared with wild type mice (Kim et cd., 2006). It was also shown in the 
same study that the serum and hepatic lipid levels were lowered due to increased 
fatty acid oxidation in adipocytes isolated from epididymal adipose tissue (Kim et al., 
2006). D e Souza et al. (2001) reported that the products of P 3 - A R - m e d i a t e d lipolysis 
(e.g. glycerol and free fatty acids) provide fuel for thermogenesis driven by brown 
adipose tissue, resulting in an overall decrease in whole body adiposity and body 
weights. In non-obese rats, p3-AR-mediated lipolysis would also have the effect of 
decreasing the size of the adipocytes resulting in a population of smaller, more 
insulin sensitive adipocytes, leading to an increase in the adipose tissue glucose 
uptake (de Souza et al., 1997). The present results therefore further support the 
beneficial role of P3-AR agonist in ameliorating obesity. Inhibition of B R L 
37344-inudced lipolysis by bupranolol (a Pi/p2/p3-ARs antagonist) and S R 59230A 
(a p 3 - A R antagonist) suggests that fc-AR plays an important role in the lipolytic 
response, as demonstrated in isolated rat epididymal adipocytes (Canova et al., 2005). 
Indeed, p 3-AR subtype is the most abundant and is predominantly involved in the 
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functional activity of these cells (Germack et al., 1997; Murphy et al., 1993). It was 
recently shown that specific p 3 - A R activation significantly stimulated nitric oxide 
(NO) production in cultured rat epididymal adipocytes, with a lipolytic effect 
several-fold more potent as compared to non-selective p-AR activation by 
isoprenaline. The B R L 37344-induced lipolysis as well as the production of N O were 
inhibited by bupranolol, indicating N O produced downstream of p 3 - A R is involved 
in lipolysis (Canova et al； 2006). It is therefore possible that a reduced N O 
production from the adipocytes in +db/+db mice leads to the reduced lipolytic 
> 
response upon p 3-AR activation, as demonstrated by the attenuated relaxation in 
isolated thoracic aorta elicited by acetylcholine (an NO-dependent mechanism) in 
this strain of mouse (Lam et al., 2006). B R L 37344 has been shown to be an agonist 
highly selective for p 3-AR subtype in rat white adipocytes (Germack et al., 1997). 
However, in the present study, nadolol (a P丨/p2-ARs antagonist) and ICI 118,551 (a 
P 2 - A R antagonist) suppressed B R L 37344-induced lipolysis in both strains of mouse. 
This indicates that the lipolytic effect of B R L 37344 is also partly 
Pi/p2-AR-mediated. Indeed, it has been demonstrated that B R L 37344 increased 
atrial rate (a Pi-AR-mediated response) and caused uterine relaxation (a 
p2-AR-mediated response) in Sprague-Dawley rats, implicating that B R L 37344 
exhibits P i/P 2-AR selectivity (Oriowo et al, 1996). 
O n tfie other hand, catecholamines modulate lipolysis by binding to different 
adrenoceptor subtypes on the cell-surface membrane of adipocytes with pronounced 
acute lipolytic/anti-lipolytic effects (Arner, 2005). It has been demonstrated that 
acute application of isoprenaline induced glycerol release in isolated adipocytes from 
wild-type mice and human preadipocytes culture dose-dependently (Langin et al, 
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2005). In the current study, isoprenaline triggered a concentration-dependent 
lipolysis in omental adipocytes of +m/+db and +db/+db mice, as previously 
described in the isolated rat epidydymal adipocytes (Canova et aL, 2006). It was also 
found that +db/+db mice showed a smaller magnitude in the maximal lipolytic 
response when compared with their lean littennates. It is in line with a previous study 
that isoprenaline-induced lipolysis was decreased by 4 0 % in human mature 
adipocytes from obese subjects (Langin et al., 2005). It has been suggested that 
hormone-sensitive lipase (HSL) is the major enzyme for catecholamine-stimulated 
lipolysis as isoprenaline did not induce lipolysis in adipocytes from HSL-null mice 
(Langin et al., 2005). H S L m R N A and protein expression levels were reduced in 
obese patients with insulin resistance (Jocken et al., 2007b). Thus, there m a y 
possibly be defects in H S L expression in +db/+db mice causing the ablation of 
isoprenaline-induced lipolysis. This has been demonstrated in SHR/NDmc-cp rats, 
which are the models of metabolic syndrome, that the glycerol-releasing activity on 
addition of noradrenaline diminished in slices of epididymal, retroperitoneal, and 
mesenteric adipose tissues due to the impaired expression of H S L when compared to 
lean controls (Harikai et al, 2007). Moreover, the isoprenaline-induced lipolysis was 
suppressed by ICI 118,551 (a p 2-AR antagonist) in +m/+db mice, and was 
suppressed by S R 59230A (a (33-AR antagonist) in +db/+db mice. These findings 
imply that (32- and p 3-AR are involved in the activation of lipolysis by isoprenaline. 
Adrenaline, the adrenal gland medullary hormone naturally present in the body, also 
stimulated lipolytic action in both strains of mouse in a concentration-dependent 
manner in this study. A lower maximal lipolytic response in +db/+db mice was 
observed, indicating adrenaline-induced lipolysis was altered under diabetic/obese 
conditions. Again, this m a y be related to the aberration of H S L expression in the 
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adipose tissue of +db/+db mice, as H S L is largely involved in 
catecholamine-induced lipolysis (Langin et al., 2005). Interestingly, adrenaline at 
higher concentrations (10 |liM and 100 ^ M in +m/+db mice; 100 |IM in +db/+db 
mice) showed a submaximal lipolytic response, which was not observed in rats 
(Germack et al., 2000; Germack et cd., 1997). Application of yohimbine (an ot2-AR 
antagonist) significantly increased the lipolytic response at these concentrations in 
+m/+db mice. A s introduced in section 2.1.1.1, catecholamines can activate lipolysis 
through p-AR/G s protein pathway, while inhibit lipolysis. through a 2-AR/Gj protein 
pathway (Arner, 2005). It can be deduced that at such concentrations of adrenaline, 
the anti-lipolytic signal transduced by the ot2-AR is more profound in this particular 
strain of mouse. Taken together, the lipolysis mediated by catecholamines was 
altered in +db/^db mice. 
P-adrenergic lipolysis is mediated via the (3-AR/adenylyl cyclase/cAMP/protein 
kinase A (PKA) signaling pathway (Carmen et al, 2006)，and that N O produced 
downstream of p 3 - A R / c A M P cascade is involved in lipolysis (Canova et al., 2006). 
Lipolysis stimulated by P - A R agonists occurred essentially via intracellular c A M P 
accumulation (Ohsaka et al., 1998). It is possible that there are post-receptor 
alterations in p-AR-mediated lipolysis under the diseased conditions that could 
account for the blunted lipolytic response observed in +db/+db mice. To examine 
these possibilities, the lipolytic effect of forskolin (a specific adenylyl cyclase 
activator) was evaluated. Forskolin caused a concentration-dependent lipolytic 
response in both species, which was agreed with other reports in which forskolin 
stimulated lipolysis in rats (Canova et al., 2006; Germack et al., 2000) and mice 
(Schweiger et al., 2006). In previous studies using ob/ob mice (Gettys et al, 1991) 
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and obese Zucker (fa/fa) rats (Vannucci et al., 1989), there were no significant 
differences in the magnitude of lipolytic response elicited by forskolin recorded 
under both normal and diseased conditions. However, in this study, there was a 
smaller lipolytic response elicited by forskolin in +db/+db mice compared to 
+m/+db mice, indicating there might be modifications in the adenylyl cylcase 
ftmction, which m a y be responsible for the impaired (3-AR-induced lipolysis. To 
investigate further the downstream signaling pathway of adenylyl cyclase, the 
lipolytic effect of 8-bromo-cAMP (a cell permeable c A M P analogue) was evaluated. 
It has been shown in rat adipocytes that cell permeable c A M P analogue (dibutyryl 
cyclic-cAMP) stimulated glycerol release in isolated rat adipocytes (Canova et al., 
2005; Tavernier et al., 2005). In this study, there was a moderate stimulation of 
lipolysis in both species, as compared with the drug challenge at receptor level. 
Interestingly, it appeared that the glycerol released in response to activation by 
different agonists was gradually reduced along the downstream cellular signaling 
pathway. It is postulated that the permeability of the c A M P analogue into the isolated 
adipocytes from these strains of mouse m a y be lowered since the adipocyte is a large 
cell, and 8 0 % of the volume of which consists of one or more lipid vacuoles (Klaus, 
1997). It has also been shown that a significant increase in glycerol increase was only 
observed at a high concentration (1 m M ) as demonstrated in various studies (Canova 
e t a
“ 2005; Canova et al., 2006). It is noted that 8-bromo-cAMP elicited comparable 
lipolysis in the adipocytes from ob/ob mice and their lean counterparts (Gettys et al., 
1991). The present findings, in contrast, demonstrated that the maximal lipolytic 
response of +db/+db mice was lower compared to +m/+db mice. Since this 
experimental approach bypasses the regulatory steps prior to P K A activation, it is 
possible that a malfunction of the downstream signaling cascade (e.g. P K A / H S L ) 
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could contribute to the discrepancy of the lipolytic action elicited by 8-bromo-cAMP 
in +db/+db mice, as previously described that a decreased P K A activity in 
streptozotocin (STZ)-induced diabetic rats resulted in the reduced vascular relaxation 
responsiveness to 8-bromo-cAMP in mesenteric artery (Matsumoto et al, 2004). 
The role of N O in biological systems is controversial and complicated, depending on 
its levels, type of tissue, location, redox status and whether it is an in vivo or in vitro 
study (Farghali et al, 2003). Sodium nitroprusside (SNP, an exogenous donor of N O ) 
(1 - 5 ^iM) was found to stimulate lipolysis, but S N P (25 - 500 ^ M ) inhibited 
lipolysis in adipose tissue of obese humans, in a concentration-dependent manner 
(Jobgen et al., 2006). In this study, S N P (an exogenous donor of N O ) did not cause a 
change in the baseline lipolysis in both strains of mouse. Canova et al (2006) 
showed that S N A P (10 - 200 [iM) did not significantly alter baseline lipolysis after 
24 h incubation until a high drug concentration was reached (250 jiM). S N A P at even 
higher concentrations (0.5 - 2 m M ) was suggested to increase baseline lipolysis in rat 
abdominal and epidydymal adipocytes probably via a S-nitrosylation-mediated 
inhibition of phosphodiesterase (Gaudiot et al, 1998). The present observation 
therefore indicates a species difference in SNP-induced lipolytic effects. Although 
N O can activate a guanylyl cyclase and protein kinase G (PKG)-dependent pathway 
(Langin, 2006), dibutyryl-cGMP (a cell permeable c G M P analogue) failed to alter 
the baseline lipolysis in both strains of mouse, consistent with a previous study in 
which 8-bromo-cGMP did not have any effect on adipocyte lipolysis (Canova et aL, 
2006). A specific inhibition of soluble guanylyl cyclase pretreatment of isolated 
adipocytes from Sprague-Dawley did not prevent the increased SNAP-induced 
lipolysis (Gaudiot et al, 1998). These results suggest that lipolysis in these mice was 
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probably not mediated through the NO/guanylyl cyclase/cGMP/PKG signaling 
cascade，and that it is possible that N O regulates lipolysis via different 
mechanism(s). 
The present results demonstrated that the P-AR-mediated lipolysis of the omental 
adipocytes was attenuated in +db/+db mice. This P-AR-mediated lipolytic action 
was suppressed by various P-ARs antagonists, suggesting the involvement of (3-ARs 
in the regulation of lipolysis of the omental adipocytes. In differentiated human 
preadipocytes，there was no difference in the protein expression of the p 2 - A R 
between non-obese and obese subjects (Langin et al, 2005). However, it has been 
shown that genetic variability in the p2-adrenoceptor ( A D R B 2 ) gene in overweight 
and obese human subjects is associated with the disturbance in in vivo p - A R 
-mediated lipolysis (Jocken et al, 2007a). Lean human subjects with low 
isoprenaline sensitivity, as measured by in vitro abdominal subcutaneous fat cell 
lipolysis, appeared to have lower p 2 - A R number and m R N A level compared with 
lean subjects with high isoprenaline sensitivity (Lonnqvist et al., 1992). The 
impaired gene expression of p r A R was responsible for the defects in 
catecholamine-stimulated lipolysis in ob/ob mice (Collins et al., 1994). It is therefore 
possible that an alteration of p 2- and p 3 - A R expression under diabetic/obese 
condition could be contributed to the attenuated lipolytic response observed. In 
+db/+^b mice, the p 3 - A R ( m R N A and protein) expression level was 〜3-fold lower 
than that observed in +m/+db mice. In contrast, only the protein (but not m R N A ) 
expression level of p 2 - A R was 2.4-fold lower in +db/+db mice, compared to 
+m/+db mice. These results therefore suggest that the translation process of p 2 - A R 
in the adipose tissue of +db/+db mice was impaired, while there were defects at both 
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transcriptional and translational level for ps-AR expression. These results parallel 
another study in which the abdominal subcutaneous adipocytes in human subjects 
with upper-body obesity showed a diminished lipolysis in response to noradrenaline 
challenge, due to post-transcriptional defects in p 2-AR expression, but not a change 
in m R N A level (Reynisdottir et al., 1994). It has also been proposed in a study using 
STZ-induced diabetic rat that a change in m R N A levels is not necessarily associated 
with a similar change in steady-state protein levels. The rate of p 2 - A R protein 
degradation might be elevated in long-term diabetes (Dincer et al., 2001). Taken 
together，it is tempting to suggest that a reduction of the (3-AR-mediated lipolysis 
observed in +db/+db mice was probably due to a reduced p2- and p 3-ARs expression 
in the omental adipocytes. 
Folic acid (or folate) is essential in several important biochemical reactions, 
including methylation reactions (Stanger et al, 2004)，formation and transfer of 
'one-carbon units' to purines and pyrimidines in the biosynthesis of D N A (Krebs et 
al., 1976) and the conversion of homocysteine to methionine (Brouwer et al., 1998). 
Impairment of folate metabolism is associated with hypomethylation, D N A damage, 
impaired cell proliferation and malignancies (Stanger, 2002). However, the possible 
effect of folic acid in the regulation of lipid metabolism, especially in lipolysis, is 
relatively unclear. 
The plasma concentration of folic acid is 〜10 nmol/L (Brouwer et al., 1998) and the 
recommended daily intake of folate is suggested as 400 |_ig/70 kg/day for adults (the 
U S A Food and Drug Administration (FDA), 2006). Surprisingly, folate deficiency is 
the most c o m m o n vitamin deficiency even in developed countries (Stanger, 2002). 
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Deficiency in folic acid results in hyperhomocysteinemia, which is associated with 
an increased risk of cardiovascular disease, especially in T 2 D M (Hoogeveen et al, 
1998; Stanger et al., 2004). In a recent randomised, double blind, placebo controlled 
study, supplementation of folic acid (800 jig/day, 3 years) has been shown to provide 
benefits in cognitive decline and some forms of dementia which are associated with 
lower plasma folate level, including Alzheimer's disease (Durga et al., 2007). 
Increased intake of folate is associated with a 6 0 % reduction in tumour development 
in ulcerative colitis (Lasliner et al, 1989). In T 2 D M , in which the serum folate level 
is not altered, short term oral folic acid supplementation (10 mg/day, 3 months) also 
caused a significant fall in heat shock protein 70 (Hsp 70) level, the protein which 
increases as a result of oxidative stress (Hunter-Lavin et al., 2004). Folate is 
therefore suggested as an effective antioxidant owing to the reduced production of 
free radicals via the reduction of homocysteine level (Racek et al.’ 2005). In fact, 
oxidative stress has been proposed to be a potential pathogenic mechanism linking 
obesity and insulin resistance with endothelial dysfunction (Ceriello et al., 2004). 
Decrease in oxidative stress has been observed in obese individuals after dietary 
restriction and weight loss (Van Gaal et al., 2006). It is anticipated that the 
antioxidant effect provided by folic acid supplementation would improve both the 
resting and agonist-stimulated lipolytic response in +db/+db mice. 
It is well known that hyperhomocysteinemia promotes the raised formation of 
reactive oxygen species (ROS) (Hayden et al., 2004), endothelial dysfunction due to 
diminished nitric oxide release (Setola et al., 2004; Signorello et al., 2007) and 
potentiation of L D L oxidation (Medina et al., 2001); and folate treatment provides 
beneficial effects to these phenomena via a decrease in plasma homocysteine levels 
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(Racek et al., 2005; Setola et al., 2004). Interestingly, it has been shown that folic 
acid supplementation restored the impaired endothelium-dependent vasodilation in 
subjects without elevated homocysteine concentrations, suggesting that folic acid 
also possesses distinctive effects independent of homocysteine lowering (Verhaar et 
al., 1999; Wilmink etal., 2000). 
Limited researches have been performed on the regulation of lipolysis by 
antioxidants. Nonetheless, it has been demonstrated that vitamin C showed lipolytic 
effect in 3T3-L1 cells by inhibiting triglyceride accumulation (Hasegawa et al., 
2002). Catechin, a well known antioxidant present in green tea, had a strong lipolytic 
activity in differentiated 3T3-L1 cells possibly through the inhibition of acetyl-CoA 
carboxylase activity (Watanabe et al., 1998) and stimulation of H S L translocation 
(Mochizuki et al, 2004). In the present study, folic acid (5.7 jig/kg and 71 p,g/kg) 
significantly reduced the total body weight of +db/+db mice by 〜8.5% over the 
course of the 4-week treatment. The decrease in body weight of +db/+db mice m a y 
be, to a certain extent，due to an increase in the basal rate of lipolysis of the omental 
adipocytes, as this results in the mobilization and utilization of the lipid fuel (Langin, 
2006). In addition, resistin, a novel adipocyte-derived polypeptide, is implicated as a 
factor linking obesity and diabetes by impairing insulin sensitivity and glucose 
tolerance. It has been reported that resistin affected insulin-stimulated glucose uptake 
by decreasing the intrinsic activity of cell surface glucose transporters in L6 rat 
skeletal muscle cells (Moon et al., 2003). In fact, previous report showed that the 
serum resistin level was dramatically raised in ob/ob and db/db mice (Steppan et al., 
2001). It is possible that folic acid m a y improve the diabetic/obese condition of 
+db/+db mice through the reduction of resistin level. 
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Apart from the reduction in body weight, it was demonstrated that folic acid 
treatment (5.7 p,g/kg and 71 pg/kg) enhanced the concentration-dependent lipolytic 
response elicited by the p2-AR agonist salbutamol in isolated omental adipocytes of 
+db/+db mice. A n enhancement of lipolysis triggered by C G P 12177A (provided by 
folic acid 5.7 jag/kg) and B R L 37344 (provided by folic acid 5.7 |j.g/kg and 71 |^g/kg) 
in +db/+db mice was observed. These results suggest that folic acid could probably 
increase the sensitivity to lipolytic response mediated by the P2- and p 3 A R subtype 
under the diabetic/obese conditions. It has been demonstrated that T 2 D M patients 
display a significantly higher plasma homocysteine and basal R O S level, in which 
the two markers are strictly correlated (Signorello et al., 2007). Perhaps, the 
increased oxidative stress is responsible for the attenuated lipolytic responses in 
+db/+db mice, as previously demonstrated by Gaudiot et al. that the exposure of 
isolated rat epididymal adipocytes to an extracellular generating system of oxygen 
species (xanthine/xanthine oxidase) or to H2O2 resulted in an inhibition of lipolytic 
response to dibutyryl-cAMP (Gaudiot et a!., 2000). It is therefore speculated that 
folic acid, in the current study, m a y enhance the P-AR-mediated lipolytic effect by 
the reduced production of free radicals via the reduction of homocysteine level 
(Racek et al., 2005). This agreed with the previous report that two antioxidants, 
ascorbate and diethyldithiocarbamic acid (DDC) reversed the anti-lipolytic effect of 
diphenyliodonium (DPI), a nitric oxide synthase (NOS) inhibitor, owing to their 
scavenging properties toward oxygen species (Gaudiot et al., 2000). 
It was previously reported that lipolytic catecholamine resistance is present in human 
subjects with abdominal obesity. However, obesity did not influence the resting 
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plasma catecholamine levels in these patients (Reynisdottir et al., 1994). In the 
present study, folic acid (5.7 pg/kg) significantly enhanced the lipolytic response 
elicited by adrenaline in +db/+db mice. In patients with severe insulin resistance, 
folate treatment reduced insulin levels, while it improved insulin resistance in 
patients with metabolic syndrome (Setola et al., 2004). Improvement in insulin 
resistance thereby promotes the better control of insulin anti-lipolytic effect (Langin, 
2006). The current data support that folic acid supplements m a y also provide 
beneficial effects to patients with abdominal obesity, which is caused by 
catecholamine resistance rather than a diminished catecholamine release. 
A s discussed above, the blunted lipolytic response observed in +db/+db mice was 
probably due to the post-receptor alterations in P-AR-mediated lipolysis. Hence, it is 
tempting to investigate whether folic acid can improve the attenuated lipolysis at the 
post-receptor level. The present data demonstrated that both forskolin- and 
8-bromo-cAMP-induced lipolysis in +db/+db mice were enhanced by 〜30。/。and 
〜20%, respectively, after folic acid treatment (5.7 fig/kg and 71 j-ig/kg). It is possible 
that folic acid may prevent the P K A inactivation by R O S (Dimon-Gadal et al., 1998; 
Raynaud et al., 1997), and consequently enhance the phosphorylation of H S L 
causing lipolysis (Carmen et al., 2006). A s demonstrated by our data previously, 
lipolysis in these mice was probably not mediated through the NO/guanylyl 
cyclase/cGMP/PKG signaling cascade. Previous reports have shown that 
administration of folate restored impaired NO-dependent vasodilation in T 2 D M 
patients (van Etten et al., 2002). Endothelial function assessed by post-ischemic 
maximal hyperemic vasodilation was improved in patients with metabolic syndrome 
after folate treatment (5 mg/day, 1 month) by an increased c G M P level (Setola et al., 
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2004). However, folic acid, in the present study, did not provide additional change in 
the lipolysis in response to dibutyryl-cGMP and SNP. It is possibly due to the 
discrepancy existing across different biological systems, as the diversified role of N O 
largely depends on different types of tissue as well as different species (Canova et al., 
2005). Taken together, it is suggested that folic acid m a y alter the adenylyl cyclase 
function/activity as well as the downstream signaling cascade (e.g. P K A / H S L ) 
(Carmen et al., 2006), under diabetic/obese conditions. 
The data of the present findings indicate that folic acid (4-week oral administration) 
improved the baseline as well as the P-AR-mediated lipolysis of the omental 
adipocytes in both strains of mouse. Down-regulation of the p 3-AR m R N A levels 
was observed in brown adipose tissue from rats as a retroregulatory response to the 
chronic sympathetic stimulation associated with the sustained high energy intake of 
cafeteria diet (Roca et al, 1999). Alteration of p 3-AR m R N A transcripts in hyper-
and hypothyroid rats, respectively, were shown to be responsible for the control of 
lipolytic activity (Germack et al., 2000). Anti-thyroid treatment in patients with 
thyrotoxicosis restored the abnormally enhanced catecholamine-induced lipolysis by 
a decrease in the number of p 2-AR (Lonnqvist et al, 1992). It is therefore possible 
that a modification of p2- and (33-AR expression after folic acid treatment could be 
attributed to the enhancement of p-AR-mediated lipolytic responses observed. 
Interestingly, folic acid (71 |ag/kg) significantly suppressed the m R N A expression of 
P 2-AR in +m/+db mice, while folic acid (5.7 pg/kg and 71 pg/kg) did not cause a 
significant change in m R N A expression of (32-AR in +db/+db mice. Similarly, folic 
acid (5.7 pg/kg: and 71 jig/kg) reduced the m R N A expression of p 3-AR in +m/+db 
mice, but caused no significant change in the m R N A expression of (33-AR in 
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+db/+db mice. It appears that the improvement in lipolytic response upon p_AR 
activation in the omental adipocytes in these strains of mouse after folic acid 
administration was not due to a concomitant increase in receptor m R N A expression. 
Similarly, folic acid (71 fj,g/kg) significantly decreased the p 2-AR protein expression 
of both +m/+db and +db/+db mice. In contrast, folic acid treatment (5.7 ^ ig/kg and 
71 |^g/kg) significantly increased the p 3-AR protein expression of +db/+db mice. 
The protein expression of p 3-AR of +db/+db mice was also significantly higher than 
that of +m/+db mice after folic acid treatment (5.7 jig/kg and 71 |ng/kg). Thus, these 
results suggest that the enhancement of the P-AR-mediated lipolysis observed in 
+db/+db mice by folic acid treatment was related to the increase in p 3-AR protein 
expression. Nevertheless, it is noteworthy that the m R N A expression ratio of (32-AR 
in +db/+db mice to +171/+db mice was actually increased after folic acid treatment 
(control: 0.63:1; folic acid (5.7 |ig/kg): 1.06:1 and folic acid (71 pg/kg): 3.75:1), and 
this phenomenon was also observed for (33-AR (control: 0.55:1; folic acid (5.7 (ig/kg): 
0.96:1 and folic acid (71 |_ig/kg): 1.63:1). Llado et al. (2000) demonstrated that the 
enhanced p3-AR-mediated lipolytic response in isolated rat adipocytes was due to an 
increase in the intrinsic activity of p 3-AR. It was also reported that the level of 
coupling of p 3-ARs to G-proteins was responsible for the change in functional 
lipolytic sensitivity to P-AR agonists in rat white adipocytes (Germack et al., 2000). 
Therefore, the enhancement of the P-AR-mediated lipolysis observed in +db/+db 
mice by folic acid treatment was probably due to an increase in p 3-AR protein 
expression, but not directly related to the change in p 2-AR expression of the omental 
adipocytes. However, the possibility of increased activity or coupling effect of both 
the p 2- and (33-ARs cannot be ruled out. 
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In summary, folic acid (4-week oral administration) provides an enhancement effect 
on P-AR-mediated lipolysis in +db/+db mice, probably related to an alteration in the 
P-AR/adenylyl cyclase/cAMP/PKA signaling pathway and an increase in the (33-AR 
protein expression of the omental adipocytes. Additional work has to be carried out 
to further elucidate the underlying mechanisms of such alteration. After all, results of 
the present study seem to strengthen the evidence that folic acid treatment has 
beneficial effects in ameliorating diabetes/obesity. 
In addition to folic acid, the possible beneficial effect of a traditional Chinese 
medicine, Lingzhi {Ganoderma lucidum), in improving the metabolic abnormalities 
in T 2 D M was also investigated. The well known therapeutic uses of Lingzhi are 
related to its immuno-modulatory effects (Miyazaki et al., 1981) and the anti-tumour 
properties (Wang et al., 1997). Although there have been numerous studies 
demonstrating the hypoglycemic and anti-diabetic effects of Lingzhi (Huie et al., 
2004; Jong et al., 1992; Li et al., 2004), its effect on lipolysis has not received much 
attention. Jung et al (2006) reported that Lingzhi extract increased glucose uptake by 
about 2-fold when compared to controls in rat isolated skeletal muscle cells via an 
activation of phosphatidylinositol (PI) 3-kinase pathway. Lingzhi polysaccharides 
(125 and 250 mg/kg, 8 weeks) lowered the raised serum glucose and triglyceride 
levels in STZ-induced diabetic mice, suggesting the potential anti-diabetic effect in 
T l D M - ( H e et al, 2006). In the present study, Lingzhi (water-extract, 4-week oral 
administration) did not modify the forskolin-induced lipolysis in omental adipocytes 
of both strains of mouse (a well-established adenylyl cyclase-mediated lipolytic 
response), compared to respective control. In consistence with a previous study that 
Lingzhi supplementation (1.44 g Lingzhi extract/day, 4 weeks) in human subjects did 
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not significantly change the plasma lipid level (Wachtel-Galor et al., 2004), the 
present results suggest that the beneficial effect of Lingzhi in T 2 D M is not likely to 
be related to an enhanced lipolytic response upon adenylate cyclase activation. 
However, the possibility that modification of lipolysis through other signaling 
pathways by Lingzhi cannot be ruled out. 
5.2. Studies on peroxisome proliferator-activated receptor-y 
The functions and mechanisms of the peroxisome proliferator-activated receptor-y 
(PPAR-y) cascade of the adipose tissue are controversial. Previous reports have 
suggested that PPAR-y plays an essential role in lipogenesis (Camp et al., 2001; 
Kubota et al., 1999)，and the regulatory role of PPAR-y on lipogenesis has been 
demonstrated in heterozygous PPAR-y mutant mice (Camp et aL, 2001). O n high-fat 
diet, the PPAR-y heterozygous mice gained a lesser weight with a significantly 
smaller fat store than the wild-type mice. 
Although the contribution of PPAR-y on lipogenesis has been extensively studied, 
the therapeutic effects of PPAR-y agonists in most studies are obvious only after a 
chronic (long-term) use. However, it is well-documented that there are c o m m o n 
metabolic and physiological changes, such as oedema and body weight gain, 
observed after a long-term treatment with thiazolidinediones (Sotiropoulos et al., 
2006). In this study, the acute effect of PPAR-y agonist on lipolysis was thus 
evaluated, so as to avoid physiological changes occurred (after a long-term 
administration) that can complicate an accurate interpretation of the results. So far, 
most effort has been focused on h o w PPAR-y agonist altered the lipolysis 
phenomenon elicited by different lipolytic agents. It has been shown that chronic 
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treatment of rosiglitazone in rats (7 days with 15 mg/kg of rosiglitazone per day) 
increased basal and noradrenaline-stimulated lipolysis by the augmented expression 
levels of genes encoding adipose triglyceride lipase and monoglyceride lipase 
(Festuccia et al., 2006). 12 weeks of troglitazone therapy (400 mg/day) enhanced the 
suppression of fatty acid release into plasma by insulin as shown by a reduced rate of 
appearance in obese human subjects with T 2 D M (Racette et al., 2002). A s mentioned 
in the previous section, there was a 〜3-fold higher baseline lipolysis in +m/+db mice 
compared to that in +db/+db mice. It is tempting to speculate that an attenuation of 
the baseline as well as the agonist-induced lipolysis plays an important role in the 
development of obesity. Unfortunately, all PPAR-y agonists tested failed to alter the 
baseline lipolysis in both +m/+db and +db/+db mice suggesting that an acute 
activation by PPAR-y agonists produced no apparent lipolysis of the omental 
adipocytes. Since a transcription of thiazolidinedione-response genes (e.g. Glut-1) is 
regarded as the principal mechanism through which T Z D s exert their effects through 
the activation of PPAR-y (Kahn et al, 2000), this m a y explain the absence of 
lipolytic effects in the omental adipocytes in both strains of mouse by the acute 
application of PPAR-y agonists tested. 
In obese Zucker rats (Gorla-Bajszczak et al, 2000), the PPAR-y expression in white 
adipose tissue was 2-fold higher compared to the lean rats. Insulin-deficient (STZ) 
diabetes suppressed adipose tissue PPAR-y expression by 7 5 % when compared to 
normal controls (Vidal-Puig et al., 1996). Consistent with previous studies (Shimoike 
e t a
!,, 1998; Vidal-Puig et al, 1996), PPAR-y ( m R N A and protein) is expressed in the 
adipose tissue of both +m/+db and +db/+db mice. However, there was no significant 
difference in the expression of PPAR-y between these species. Despite the fact that 
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PPAR-y is expressed in the omental adipose tissue of both species, it only contributes 
minimally to the acute lipolytic response of omental adipocytes in both +m/+db and 
+db/+db mice. 
5.3. Studies on HMG-CoA reductase 
Statins are well known for the inhibition effect on H M G - C o A reductase, the 
rate-limiting enzyme for the endogenous cholesterol synthesis in the liver and 
intestine (Feingold et al., 1994). They also display a wide range of 
cholesterol-independent (pleiotropic) effects which are beneficial for T 2 D M , such as 
stimulation of endothelial nitric oxide synthase (Hernandez-Perera et al., 1998) and 
inhibition of reactive oxygen species (ROS) production (Pahan, 2006). It has been 
shown in cultured differentiated murine white adipocytes that acute treatment of 
atorvastain (1 \xM and 10 p,M, lh), which is considered as one of the most potent 
statins, resulted in a dose-dependent reduction in insulin-induced glucose uptake by 
maximally 20%. In the same study, chronic treatment of atorvastatin (10 72 h) in 
differentiating preadipocytes resulted in a diminished lipid accumulation as detected 
by microscopy (Mauser et al, 2007). Pravastatin given as food mixture (0.03 or 
0.06%, 2 or 4 weeks) suppressed the elevation of plasma glucose, enhanced 
insulin-induced glucose uptake in adipose tissue, improved insulin resistance and 
glucose intolerance in the +db/+db mice (Takagi et al., 2007). Although side-effects 
secondary to long-term statin therapy are not very common, it has been reported that 
the occurrence of myopathy, the most c o m m o n side-effect with symptoms ranging 
from fatigue, weakness, and pain, m a y be 1-5% or more (Dirks et al., 2006). A rare 
but life-threatening condition, rhabdomyolysis, is also associated with long-term 
statin use (De Angelis, 2004). In order to minimize the occurrence of these adverse 
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effects, the acute effect of statins on lipolysis in adipocytes was investigated. A s 
demonstrated in the previous section, a 〜3-fold higher baseline lipolysis was 
observed in +m/+db mice compared to that in +db/+db mice. It is speculated that a 
diminished baseline and agonist-induced lipolysis may play an important role in the 
development of obesity. Unfortunately, all statins tested failed to alter the baseline 
lipolysis in both +m/+db and +db/+db mice suggesting that an acute application of 
statins produced no apparent lipolysis in the omental adipocytes. 
O n the other hand, it was shown in this study that H M G - C o A reductase exists in 
various internal organs of mice (+m/+db mice and +db/+db mice). It is generally 
believed that the statins are mainly responsible for the clinical beneficial effects (i.e. 
cholesterol-lowering effects) (Grundy, 1988), but recent studies suggested otherwise, 
such as reduction in cardiovascular events in patients with average cholesterol levels 
(Byington et al., 1995; O'Driscoll et al., 1997; Sacks et al., 1996). In this study, w e 
have systematically demonstrated that H M G - C o A reductase (both m R N A and protein) 
expressed, in a differential fashion, in all organs examined. The physiological 
importance of the differential expression of this enzyme in different organs remains 
to be determined. 
The existence of extra-hepatic sterol synthesis has been demonstrated by measuring 
the rate of sterol synthesis using
 3
H-labeled digitonin-precipitable sterols in rat and 
rabbit (Andersen et al., 1982; Dietschy et al., 2004). Interestingly, it has been 
suggested that liver is quantitatively less important as a site for sterol synthesis than 
previously believed. In fact, most sterol utilized by the extra-hepatic tissues is largely 
de novo synthesized (Spady et al,, 1983) but the role of the hepatic H M G - C o A 
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reductase received most of the attention simply because of the effectiveness of 
H M G - C o A reductase inhibitors (i.e. statins) in treating different 
hypercholesterolemia-related diseases (Grundy, 1988). It was recently reported that 
streptozotocin diabetic rats fed with high-fat diet induced a higher H M G - C o A 
reductase m R N A expression in liver when compared to controls (Lally et aL, 2007). 
A s shown in the current study, T 2 D M does not cause an alteration in H M G - C o A 
reductase expression in liver, as revealed by the similar expression levels in +m/+db 
and +db/+db mice. 
The presence of extra-hepatic H M G - C o A reductase in different internal organs is 
probably related to the localized physiological function(s) of this enzyme. 
Cholesterol is a major constituent of the plasma membrane in animals (Lange et al., 
1989) and is required for growth (Yeagle et al., 1988) and development (Jurevics et 
al., 1994). For example, the anatomical architecture of the brain (e.g. formation of 
myelin of axon/neuron) is mainly composed of cholesterol, and plasma lipoproteins 
are unable to cross the blood-brain barrier (Michikawa et al., 1999; Vance et al., 
2005). Therefore, the "localized" existence of H M G - C o A reductase (Dietschy et al., 
2004) in the brain, as revealed in our study, offers beneficial advantages in relation to 
the structural/physiological needs of a particular organ. 
It has-been reported that ~1 % of pulmonary surfactant cholesterol is derived from 
endogenous synthesis in lungs (Gunasekara et al., 2005; Leonenko et al., 2006) with 
the rest being supplied by serum lipoproteins. In addition, both low (LDL)- and 
high-density lipoprotein (HDL) are present in lungs and the cholesterol metabolism 
is regulated "locally" (Hass et al, 1980). It has been reported that simvastatin 
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markedly reduced total cholesterol in lamellar body and alveolar compartments of rat 
lungs (Davidson et al., 1997). In rats (Moxley et al, 1977)，the drug-induced (by 
alloxan or streptozotocin) diabetes resulted in a decrease in the synthesis of the lipid 
components of the pulmonary surfactant. In our study, H M G - C o A reductase is 
detected in lungs, with a relatively higher m R N A expression in +m/+db mice, 
compared to +db/+db mice. In view of the importance of the pulmonary surfactant in 
lungs functions, it is tempting to speculate that an attenuated m R N A expression of 
H M G - C o A reductase observed in +db/+db mice may be related to the impaired lung 
functions associated with obesity and insulin resistance occur in m a n (Lin et al., 
2006) and diabetic hamsters (Popov et al., 1997). It is important to point out that 
pulmonary structural/functional abnormalities observed in diabetes is generally 
parallel to that in kidneys and skeletal muscle, supporting a c o m m o n pathogenesis 
(Popov et al., 1997; Raskin et al., 1983; Rosenstock et al., 1986). Irrespective of the 
type of mice used in our study, a similar profile of protein expression of H M G - C o A 
reductase was observed, i.e. the highest level was found in both lungs and kidneys 
whereas the lowest level was observed in abdominal fat tissues. In addition, a similar 
magnitude of reduction (〜60%) of the m R N A expression of H M G - C o A reductase, as 
was observed in the lungs, was detected in the skeletal muscle of +db/+db mice, 
compared to +m/+db mice. 
Inhibition of H M G - C o A reductase by statins not only decreases the biosynthesis of 
cholesterol but also the biosynthesis of the lipophilic side chain of ubiquinone 
(Dallner et al‘, 2000; Faust et al., 1980) and the level of ubiquinone in human 
skeletal muscle (Paiva et al, 2005). Ubiquinone plays an important role in the 
mitochondrial respiratory functions of skeletal muscles (Schaefer et al., 2004) and 
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cardiac muscle (Folkers et al., 1990; Ichihara et al., 1993; Satoh et al., 1995). A 
reduced mitochondrial oxidative phosphorylation in skeletal muscle has been 
suggested as a primary defect causing insulin resistance and the development of 
T 2 D M in m a n (Kelley et al., 2002; Petersen et al., 2003; Ritov et al., 2005). It is 
anticipated that a reduced level of ubiquinone (inhibition of H M G - C o A reductase or 
a reduced H M G - C o A reductase expression) observed in the skeletal muscle of 
+db/+db mice (i.e. a lower m R N A , but not protein, expression of H M G - C o A 
reductase) in our study may suggest an important role of H M G - C o A reductase in 
T 2 D M . In addition, a decreased m R N A but not protein expression of H M G - C o A 
reductase was observed in the lungs and skeletal muscle of +db/+db mice. Our 
results m a y therefore suggest that mechanism(s) exists in these tissues that enhances 
the translation in +db/+db mice so as to maintain a normal protein level of 
H M G - C o A reductase for the necessary functions of this enzyme. 
In addition, a positive correlation between a decreased cardiac ubiquinone level and 
the risk of cardiac dysfunction has been suggested (Yamazaki et al., 2006). There 
was, however, no difference in the m R N A expression of H M G - C o A reductase of the 
heart between +m/+db and +db/+db mice. Our results therefore suggest that, 
although the m R N A expression of H M G - C o A reductase is lower than that detected in 
the liver, obesity/diabetes has no effect on the expression of H M G - C o A reductase in 
the heart. 
O n the other hand, the de novo synthesis of cholesterol is highly active in the kidneys 
of rats (Jurevics et al., 1994) especially when they are fed with cholesterol-free diet. 
The expression of H M G - C o A reductase increased in response to systemic heat shock 
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or glycerol-induced myohaemoglobinuria which can lead to renal damage because of 
an accumulation of cholesterol (Zager et al, 2001). Perhaps, the presence of 
H M G - C o A reductase (and its relatively high expression level) in the kidneys is 
related to the active role of this organ involved in cholesterol export (Blue et al., 
1983). 
The lowest expression of H M G - C o A reductase (both m R N A and protein levels) in 
the abdominal adipose tissue, compared to other internal organs, of both species was 
rather unexpected. A s one m a y think that the fat tissue is probably the organ that has 
a high level of the cholesterol-synthesizing enzyme. Our results, however, suggest 
otherwise. The abdominal adipose tissue is therefore merely responsible for the 
"storage/release", but not the biosynthesis, of cholesterol. The similar expression 
level of H M G - C o A reductase (both m R N A and protein) in +m/+db and +db/+db 
mice implies that the discrepancy between the baseline lipolytic responses from these 
species of mouse was probably not due to the alteration of H M G - C o A reductase 
expression. 
In contrast to the m R N A expression, a similar protein level of this enzyme in the 
same organ of both mice species suggesting that the obese/diabetes conditions do not 
alter the protein expression of H M G - C o A reductase in different internal organs. It is 
therefore suggested that there is a transcriptional difference, but not a translational 
difference, of H M G - C o A reductase. 
5.4. Further studies 
The present study demonstrated that the p-AR-mediated lipolysis in the abdominal 
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adipose tissue of diabetic obese +db/+db mice was blunted due to a decreased 
m R N A expression of P2- and (33-ARs, as determined semi-quantitatively by RT-PCR. 
In order to detect the p2- and P3-ARS m R N A expression fully quantitatively, 
techniques such as real-time P C R can be employed. The decreased protein 
expression of P2- and (33-ARs in the abdominal adipose tissue in +db/+db mice also 
accounted for the blunted lipolytic responses under obese/diabetic conditions. In 
addition to the Western blotting technique used in this study, immunofluoresence 
staining can be applied to further confirm the reduced protein expression of P2- and 
p 3 - A R s in +db/+db mice. 
It is worthwhile to further elucidate the defects of the downstream signal 
transduction pathways which are involved in the P-AR-mediated lipolysis in 
+db/+db mice. Intracellular signaling enzyme inhibitors such as I B M X (a 
non-specific phosphodiesterase inhibitor) and S Q 22,536 (an adenylyl cyclase 
inhibitor) can be used. Determination of the variation in the adenylyl cyclase activity 
can be carried out by measuring the amount of c A M P formation from the abdominal 
(omental) adipocytes by radioimmunoassay. 
5.5. Conclusions 
Obesity and T 2 D M are known to be related to an aberration of the adipose tissue 
lipolyjsis. The deregulation of lipolysis leads to an excess fat mass accumulation 
which predisposes to the development of insulin resistance and the metabolic 
syndrome. Undesirable outcomes such as hypertriglyceridemia and atherogenesis 
occur and deteriorate the patients' conditions. In the current study, the mechanisms of 
the regulation of lipolysis under obese/diabetic conditions have been examined. 
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Animal models are useful in scientific research since they can mimic the disease 
conditions as in human. Preclinical trials can be carried out to study the pathology of 
the disease as well as to find out appropriate drug treatment before human 
administration. In the present study, C57BL/KsJ +db/+db mice were used as these 
animals are well established rodent models for human obesity and T 2 D M research. 
It has been demonstrated that p-ARs are present in adipocytes, and the activation of 
p 2- and P3-AR resulted in lipolysis. However, studies of the roles and the underlying 
mechanisms involved in the p-AR-mediated lipolysis, using the diabetic/obese 
rodent model C57BL/KsJ +db/+db mice, have not received much attention. A s 
shown in the current study, the baseline lipolytic response of isolated omental 
adipocytes was found to be lower in +db/+db mice when compared to +m/+db mice. 
Lipolytic response mediated through the p-ARs (as demonstrated by various (3-AR 
agonists) was also impaired in +db/+db mice, probably due to the reduced P2- and 
p 3-ARs expression (both m R N A and protein) in the omental adipocytes. A decreased 
stimulatory lipolytic response to post-receptor agents (i.e. forskolin and 
8-bromo-cAMP) in +db/+db mice also suggested that there were probably defects in 
the downstream cascade (e.g. adenylyl cyclase) of P-AR-mediated lipolysis. 
Numerous studies have demonstrated the hypoglycemic and anti-diabetic effects of 
Lingzhi. However, a 4-week oral administration of Lingzhi (water-extract) did not 
modify the forskolin-induced lipolytic response (a well established adenylate 
cyclase-mediated lipolysis response) in both diabetic (+db/+db) and non-diabetic 
(+m/+db) mice. In contrast, folic acid (4-week oral administration) appeared to 
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enhance the lipolytic responses elicited by P~AR agonists and post-receptor agents 
(forskolin and 8-bromo-cAMP) in both +db/+db and +m/+db mice. The increase in 
p 3-AR expression in +db/+db mice is probably attributed to the enhanced lipolytic 
response. However, the detailed underlying mechanisms for the beneficial effects of 
folic acid in the modulation of lipolysis in omental adipocytes remain to be 
elucidated. 
PPAR-y is known to be involved in the promotion of differentiation of adipocytes 
and lipogenesis. Although expression (both m R N A and protein) of PPAR-y was 
detected in the omental adipose tissue in both +m/+db and +db/+db mice, it only 
contributed minimally to the in vitro acute lipolytic response to PPAR-y agonists in 
omental adipocytes. 
Use of hepatic H M G - C o A reductase inhibitors (statins) has been demonstrated 
providing beneficial effect to diabetic condition, both by lowering blood cholesterol 
and their pleiotropic (cholesterol-independent) effects. Unfortunately, the acute 
application of statins did not alter the baseline lipolysis in vitro in both +m/+db and 
+db/+db mice, despite the fact that there was a low expression of H M G - C o A 
reductase (both m R N A and protein) in abdominal fat. Nevertheless, in this study, it 
has been demonstrated systematically the biochemical existence of the extra-hepatic 
expression (both m R N A and protein), in a differential manner, of H M G - C o A 
reductase in different internal organs of +m/+db and +db/+db mice. A m o n g the 
various organs examined, a transcriptional difference, but not a translational 
difference, of H M G - C o A reductase of the lungs and skeletal muscle in +db/+db 
mice was found. Given the fact that H M G - C o A reductase exist in different internal 
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organs, prescription of statins to patients with hypercholesterolemia should be 
exercised with cautions. A future study on the physiological/pathophysiological 
participation of H M G - C o A reductase, and its modulation (e.g. a non-discriminatory 
inhibition by statins), of different internal organs is warranted. These results m a y 
assist the future development/evaluation of tissue-selective statins. 
% 
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